

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030909
Article Type:	Protocol
Date Submitted by the Author:	08-Apr-2019
Complete List of Authors:	Harrison, Kristie; The University of Sydney, Faculty of Medicine and Health Lee, KS; The University of Sydney, Faculty of Medicine and Health; La Trobe University, Centre for Alcohol Policy Research Dobbins, Timothy Wilson, Scott; Aboriginal Drug and Alcohol Council of South Australia, ; The University of Sydney, Faculty of Medicine and Health Hayman, Noel; Inala Indigenous Health Service, Ivers, Rowena; Illawarra Aboriginal Medical Service; The University of Sydney, Faculty of Medicine and Health Haber, Paul; University of Sydney - Camperdown and Darlington Campus, Discipline of Addiction medicine; Sydney Local Health District, Drug Health Services Conigrave, James; The University of Sydney, Faculty of Medicine and Health Johnson, David; Aboriginal Health Council of South Australia Hummerston, Beth; Aboriginal Health Council of South Australia, Gray, Dennis ; Curtin University Bentley Campus, National Drug Research Institute Conigrave, Katherine; University of Sydney, Sydney Medical School
Keywords:	Aboriginal, Torres Strait Islander, alcohol, screening, AUDIT-C, health services

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial

Kristie H Harrison¹

KS Kylie Lee^{2, 3}

Timothy Dobbins⁴

Scott Wilson^{5, 2}

Noel Hayman^{6, 7, 8}

Rowena Ivers^{9, 1}

Paul S Haber^{10, 2}

James H Conigrave²

David Johnson¹¹

Beth Hummerston¹¹

Dennis Gray¹²

Katherine M Conigrave^{10, 2}

¹ The University of Sydney, Faculty of Medicine and Health, School of Public Health, NHMRC Centre of Research Excellence in Indigenous Health and Alcohol; C39, University of Sydney, New South Wales 2006 Australia

² The University of Sydney, Faculty of Medicine and Health, Discipline of Addiction Medicine, NHMRC Centre of Research Excellence in Indigenous Health and Alcohol; C39, University of Sydney, New South Wales 2006 Australia

³ La Trobe University, Centre for Alcohol Policy Research, Bundoora, Victoria 3083 Australia

⁴ University of New South Wales, National Drug and Alcohol Research Centre, Kensington, New South Wales 2052 Australia

⁵ Aboriginal Drug and Alcohol Council Inc., 155 Holbrooks Rd, Underdale, South Australia 5032 Australia

1
2 ⁶ Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary
3
4 Health Care, PO Box 52, Inala, Queensland 4077 Australia
5

6 ⁷ Griffith University, School of Medicine, Parklands Drive, Southport, Queensland 4215 Australia
7

8 ⁸ University of Queensland, School of Medicine, St Lucia, Queensland 4072 Australia
9

10 ⁹ Illawarra Aboriginal Medical Service, 150 Church St, Wollongong, New South Wales 2500
11
12 Australia
13

14 ¹⁰ Sydney Local Health District, Royal Prince Alfred Hospital, Drug Health Services, Missenden Rd,
15
16 Camperdown, New South Wales 2050 Australia
17

18 ¹¹ Aboriginal Health Council of South Australia, 220 Franklin St, Adelaide, South Australia 5000
19
20 Australia
21

22 ¹² National Drug Research Institute, Curtin University, 7 Parker Place, Technology Park,
23
24 Bentley Western Australia 6102 Australia
25
26
27
28
29
30

31 Corresponding author
32

33 Kate Conigrave
34

35 Drug Health Services, Royal Prince Alfred Hospital
36

37 Missenden Road
38

39 Camperdown NSW 2050
40

41 Phone +61 2 9515 8650 Email: kate.conigrave@sydney.edu.au
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Colonisation and past or current oppression often results in higher prevalence of unhealthy drinking among Indigenous peoples. In Australia, Aboriginal Community Controlled Health Services (ACCHSs) offer culturally accessible care to Aboriginal and Torres Strait Islander (Indigenous) peoples. However there are many competing priorities for staff and clients.

Methods and analysis

A randomised cluster wait-control trial will test the effectiveness of external support in increasing the rate of screening with AUDIT-C and delivery of treatment (brief intervention, counselling or relapse prevention medicines) in ACCHSs across Australia. Twenty-two services will be recruited.

Half the services will receive support soon after the trial commences (intervention or 'early support' services). The wait-control ('late support') services will receive support two years later. Each service will nominate two project champions to advocate for increasing alcohol care. Champions will attend a national training workshop and link together every two months by teleconference to share knowledge. Other support includes onsite training, and second monthly feedback on routinely collected data on screening and treatment provision.

The primary outcome will be rate of screening using AUDIT-C of individuals aged 16+ as routinely recorded on practice software ('Communicare'). Secondary outcomes will be recording of brief intervention, counselling, prescription of relapse prevention medicines; and systolic blood pressure, gamma glutamyltransferase and HbA1c. Multi-level logistic regression will be used to test the effectiveness of support.

Ethics and dissemination

Ethical approval has been obtained from eight ethics committees (Aboriginal-specific where available), including in New South Wales (#1217/16); Central Australia (#CA-17-2842); Northern

1
2 Territory (# 2017-2737); Central Queensland (#17/QCQ/9); Far North Queensland (#17/QCH/45-
3
4 1143); South Australia (#04-16-694); St Vincents Hospital (Melbourne; #LRR 036/17); and Western
5
6 Australian (#779). Results will be disseminated through direct reports to ACCHSs, peer-reviewed
7
8 publications and conference presentations.
9

10 11 12 **Trial registration**

13
14 Australian New Zealand Clinical Trials Registry (ACTRN12618001892202) retrospectively
15
16 registered on 21/11/18. Protocol version 1.
17
18
19
20
21
22
23
24
25
26
27

28 **Strengths and limitations of this study**

- 29
30 • This large cluster randomised controlled trial provides the power to test whether a model of
31
32 support for Aboriginal and Torres Strait Islander primary care services can increase rates of
33
34 alcohol screening and treatment provision.
- 35
36 • The protocol has been designed to be compatible with cultural context and to integrate western
37
38 knowledge with the expertise and holistic approaches of these services.
- 39
40 • The use of regular data feedback and nomination of service champions offers the services an
41
42 opportunity to be involved in ongoing quality improvement on alcohol care.
- 43
44 • The resultant study will be able to use routinely collected outcome data but this relies on the
45
46 accurate recording of screening and alcohol care offered to clients.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Globally, alcohol is the leading cause of death and disease for all people between the ages of 15-49 [1]. Indigenous peoples dealing with colonisation and oppression can be at higher risk of mental illness and harms from alcohol [2]. In Australia, the proportion of Aboriginal and Torres Strait Islander (Indigenous) people who drink alcohol is less than non-Indigenous people [3]. However, Indigenous Australians are 2-8 times more likely to be hospitalised for alcohol-related conditions [4] and nine times more likely to die from alcohol-related harms [5]. This directly impacts on the health gap between Indigenous and non-Indigenous Australians [4]. These increased risks and harms from drinking can be related to experiences of trauma, grief, poverty and cultural dispossession, resulting in increased mental illness, trans-generational trauma and lower life expectancy [2, 4, 6]. The lack of community autonomy and access to culturally appropriate treatment services also contribute [4].

Early detection of unhealthy drinking plays a vital role in reducing the overall burden of alcohol conditions, particularly before people develop health problems or social impacts such as incarceration related to alcohol use [7-9]. Internationally, alcohol screening and brief intervention approaches have been found to be cost-effective in reducing unhealthy drinking, particularly for those who are not dependent on alcohol [10]. Screening for unhealthy drinking aims to detect people who may be drinking above recommended limits [9]. This includes those with hazardous drinking or alcohol use disorders (AUDs) [11]. However across Australian primary care settings, screening and brief intervention for unhealthy drinking is not always standardised [12], informed by Australian National Health and Medical Research Council (NHMRC) drinking guidelines [13], or systematically conducted. It is estimated that 50-70% of people with unhealthy drinking go undetected in Australian primary care [14]. This percentage was the same (50-70% undetected) in four Indigenous primary care settings in Queensland, Australia (in 2001) [15].

Culturally-specific health care services that are led and delivered by Indigenous peoples can have a key role in improving quality of healthcare and treatment access [16]. Aboriginal Community Controlled Health Services (ACCHSs) provide accessible and culturally appropriate health care to

1
2 Indigenous communities across Australia. Each ACCHS has its own holistic-based service delivery
3
4 model for the communities that they serve [16]. As with mainstream (general population) services,
5
6 knowledge and practice of screening and brief intervention varies between and within Indigenous
7
8 primary care services [12]. Some ACCHSs have an alcohol and other drug (AOD) program, which
9
10 may include an AOD worker, program or team, or links with external AOD specialists/services.
11
12 Other ACCHSs may have no specific AOD expertise and health practitioners may lack confidence
13
14 in delivering alcohol care (i.e. screening, brief intervention, counselling or medicines). The uptake
15
16 of screening and recording of alcohol consumption data varies from service to service [17]. There
17
18 is an identified need for systems to maintain continuous quality improvement (CQI) in health care
19
20 delivery, including alcohol treatment, in ACCHSs [18].
21
22
23
24

25 There have been minimal studies of culturally-relevant tools or system support models for
26
27 ACCHSs, with even fewer conducted by Indigenous researchers [4]. AUDIT-C (the Alcohol Use
28
29 Disorders Identification Test-Consumption) is a 3-item screening tool for alcohol consumption,
30
31 comprised of the first three questions of the 10-item AUDIT (14). This short form has been shown
32
33 to have good sensitivity and specificity in comparison to the full AUDIT [19]. Prior studies suggest
34
35 that AUDIT-C is valid in Indigenous primary care settings, though further study into culturally
36
37 appropriate delivery is suggested [20-22]. To increase standardisation of alcohol screening in
38
39 ACCHSs, the use of AUDIT-C has been made a national key performance indicator (nKPI) for
40
41 ACCHSs nationally [23] and must be reported on using data collected via ACCHS' practice
42
43 software. This paper outlines the trial protocol for testing if a model of support can assist ACCHSs
44
45 to integrate the mainstream evidence base on alcohol care with their own cultural and clinical
46
47 expertise. The use of an inactive control group can be challenging on ethical and partnership
48
49 grounds, particularly for vulnerable communities. A wait-control design allows support to be
50
51 delivered to all participating ACCHSs, and enables valid comparisons to be made between
52
53 intervention and control groups.
54
55
56
57
58
59
60

Aims

This trial aims to assess if remote support for ACCHSs can result in increased uptake of evidence-based screening and treatment for unhealthy alcohol use (i.e. drinking above recommended limits). It also aims to develop and evaluate a service-wide model of support for alcohol care in ACCHSs, which builds upon services' existing strengths (see Figure 1).

(Insert Figure 1 about here)

METHODS

Overview

A cluster randomised trial will test the effectiveness of external supports to increase the use of AUDIT-C and evidence-based treatment in ACCHSs. Culturally relevant supports will be offered with the aim of increasing staff skills and capacity to develop, refine and deliver systems for alcohol care. These supports will be based on current evidence and be in-line with services' cultural-care practices. Twenty-two ACCHSs will be recruited across Australia. Services will be randomised into two arms, an early support (intervention) and a late support (wait-control) arm (Figure 2).

(Insert Figure 2 about here)

The support provided will be tailored, guided by ACCHSs, to their individual needs, including needs by remoteness. It will also be underpinned by current evidence, such as national alcohol treatment guidelines [8], Alcohol Treatment Guidelines for Indigenous Australians [24] and national alcohol consumption guidelines [13]. The study methods will be based on principles of conducting health research with Indigenous Australians [25]. This includes quality research, Indigenous involvement and engagement, benefits for Indigenous peoples, and led by Indigenous Australians.

The primary outcome will be routinely collected data on screening rates using AUDIT-C.

Secondary outcomes will include recorded delivery of brief intervention, counselling or prescribed medicines to reduce relapse in alcohol dependence. We will also describe changes in reported

1
2 drinking and in biological measures that can be affected by drinking such as gamma
3
4 glutamyltransferase (GGT; a liver enzyme), HbA1C and systolic blood pressure (BP).
5
6
7

8 **Participating services and eligibility**

9 Recruitment

10
11 This trial will recruit whole services (no clients will be recruited). ACCHSs across Australia will be
12
13 recruited based on expression of interest after circulation of study information to eligible services. A
14
15 mix of services will be approached (by KH, BH or KC) with a range of remoteness as determined
16
17 by the Australian Standard Geographical Classification – Remoteness Area (ASGC-RA) [26]. Both
18
19 verbal and written information will be shared. Face-to-face meetings will be offered to eligible
20
21 services. Resources will be designated for employing Indigenous project staff in recognition of their
22
23 specialist skills and knowledge working with ACCHSs. Additional time will be factored into project
24
25 timelines for engaging with ACCHSs, including liaising with multiple key staff, follow-up
26
27 conversations, and knowledge translation of research documents.
28
29
30
31
32

33 Inclusion criteria

34 Services eligible for the trial will meet the following criteria:

- 35 1. Are an ACCHS
 - 36 2. Provide care to 1000+ clients per annum
 - 37 3. Use Communicare as their practice software
- 38
39
40
41
42
43
44

45 Exclusion criteria

46 Services will only be excluded if signed institutional consent forms are not returned before the
47
48 close of recruitment. Data from clients aged 15 or under will not be extracted.
49
50
51
52
53

54 Consent

55 After written institutional consent is signed, a memorandum of understanding (MOU) will be
56
57 negotiated by the senior investigator (KC) and lead author (KH) with each ACCHS. Staff
58
59 participating in individual qualitative interviews will also provide informed consent. Further consent
60

1
2 will be sought, following the completion of the main trial, if the authors wish to perform ancillary
3
4 studies using stored data.
5
6
7

8 **Randomisation**

9
10 ACCHSs will be categorised into three strata based on their remoteness using ASGC-RA [26]: 1)
11 urban and inner regional; 2) outer regional and remote; 3) very remote. Service names will be
12 replaced by consecutive numbers. Within each stratum, half the services will be randomised by a
13
14 computer program into the early support arm and half into the late support arm. Randomisation will
15
16 be conducted by an author (TD) who is blind to services' names.
17
18
19
20
21
22

23 **Sample size**

24
25 Because larger numbers are needed to be able to determine increases in treatment provision than
26
27 to demonstrate an increase in screening, the treatment provision outcome was used for sample size
28
29 calculation. In an ACCHS of 1000+ clients per year, approximately 60% are likely to be aged 16
30
31 years or older [27]. We estimate that 57% of clients have likely been screened for alcohol use within
32
33 12 months [28] and at least 25% of clients who were screened are likely to be drinking above NHMRC
34
35 recommended limits [13, 29, 30]. In the late support arm, it is likely that 60% of identified unhealthy
36
37 drinkers will have an alcohol intervention recorded [28]. Assuming an Intra-cluster correlation
38
39 coefficient (ICC) of 0.04 [31, 32], enrolling 10 early support services and 10 late support services will
40
41 allow for an increase in treatment provision of at least 13% in the early support services to be
42
43 detected (i.e. from 60% to 73%; 80% power and 2-sided significance of 0.05). We will enrol an
44
45 additional service in each arm to allow for the possibility of clusters dropping out of the study.
46
47 Accordingly, the target number of services to be enrolled is 22.
48
49
50
51

52 **The model of support**

53
54 ACCHSs will be acknowledged as the experts in cultural health care for Indigenous peoples in their
55
56 communities and Australia. The study also recognises the need for flexibility based on needs of
57
58 individual services and of the ACCHS sector as a specialist sector overall. Support approaches will
59
60

include the same key elements (Table 1). However approaches will be tailored to the needs of each ACCHS, for what works best for their service, clients and communities.

Table 1. Key support elements

1.	Service champions	Services asked to nominate two representatives to act as advocates of alcohol care and links between the service and research team
2.	National workshop	National capacity building workshop for service champions at the start of the support phase (and for early support services, a wrap-up feedback workshop at the end of the maintenance support phase)
3.	Onsite training	Training will be offered to each ACCHS at their service
4.	Resources/funding	Some resources will be given to services for free with additional funding provided for the selection and purchase of further resources.
5.	Practice software (Communicare) support	Support will be provided to services throughout the trial to facilitate the routine clinical use of alcohol-related items in the practice software.
6.	Data feedback	Individual service data will be fed back to each service every second month
7.	Phone conferences	Phone conferences will be held every second month between service champions and project team (including an addiction medicine physician). These will allow sharing of ideas and joint problem solving.
8.	Online platform	Further resources and information will be shared via a secure online platform.

1
2
3
4 Continuous refinement of support approaches will occur during the trial, informed by qualitative and
5
6 quantitative data and service feedback. Early support ('intervention') services will receive the
7
8 support soon after the trial starts. Late support (wait-control) services will receive the same
9
10 intervention elements two years later. Due to the nature of the intervention, it is not possible to
11
12 blind participants or staff as to which services are receiving active support.
13
14
15

16 1. Identifying service champions

17
18 Each service will be asked to identify two representatives to work collaboratively with their service
19
20 staff and the research team on increasing alcohol care. Services will be asked to consider
21
22 nominating a clinician, Aboriginal health professional and/or an individual from management.
23
24 Service champions will be invited to attend an initial national face-to-face workshop, and second-
25
26 monthly teleconferences. These meetings will ensure that support approaches are in line with the
27
28 values of each ACCHS, and will allow sharing of expertise and initiatives. Champions will be key
29
30 in highlighting the potential benefits of change in their service and will encourage service staff to
31
32 discuss their second monthly data feedback, and to address any key barriers to change [33].
33
34
35
36

37 2. Workshops

38
39 A national workshop will be held at the beginning of each support phase to bring champions from
40
41 those services together for capacity building and networking. Feedback will be obtained from
42
43 champions about pre- and post-workshop knowledge, training preferences, alcohol priority areas,
44
45 and useful resources. Key presentations from workshops will be video-recorded and made
46
47 available via a password-protected website.
48
49
50

51
52 A wrap-up workshop will also be organised for early support service champions (only) at the end
53
54 of their support phase. Opportunities will be provided for service champions to provide verbal and
55
56 written feedback and for CQI and networking. Study results to that point will be discussed.
57
58
59
60

3. Onsite training

Training will be offered at each service for all staff, with maximum duration of two days. Core elements will include screening, alcohol and the body, brief intervention and treatment approaches, including relapse prevention medicines. Due to the individuality of each service, flexibility will be given to allow inclusion of other (alcohol-related) training topics. The training will be co-facilitated by an Addiction Specialist (KC) and an Aboriginal researcher with clinical background (KH) and will use culturally specific content and resources. Training content will be aligned with Indigenous protocols such as gender appropriateness, kinship systems and cultural obligations; such a family and community sharing, which at times can impact on substance use [21, 34]. Pre- and post-training feedback will be collected from participants.

4. Resources / Funding

The trial will provide several hard copy and electronic resources for free to services (i.e. the Handbook for Aboriginal Alcohol and Drug Work [35], Alcohol Awareness Kit [35] and Quick Reference Guide to the Treatment of Alcohol Problems [36]).

Each ACCHS will be provided with funding to purchase additional resources. Services can choose, in partnership with the chief investigators, how they spend their funding. The early support arm of the project will receive up to \$9,000 for resources. The late support arm will receive up to \$3,500. This is a reduced sum as they will have access to resources developed within the early support phase, so time and development costs will be less. Resources must be alcohol-related and may include additional training, conference attendance, resources for staff or clients, funds for health promotion events or for local adaptation of resources (e.g. translation into local language/s).

5. Practice software support

A Communicare officer will be available during the trial to support ACCHSs with the practice software. Some ACCHSs may choose to make modifications to Communicare to make alcohol 'clinical items' more accessible for staff. One example is adding AUDIT-C into the Aboriginal and

1
2 Torres Strait Islander (Indigenous) health assessment ('Adult Health Check'), which was not
3
4 routine in standard versions of Communicare at the time of trial commencement. AUDIT-C can
5
6 also be added to other regular assessments such as: antenatal and the pre-consult examination
7
8 (i.e. routine observations and/screening by a nurse or Aboriginal health worker before seeing the
9
10 doctor). Services will also be provided with information about existing 'clinical items' available on
11
12 Communicare for recording data for episodes of alcohol care (education/advice; counselling),
13
14 which can then be retrieved by data extraction.
15
16
17
18

19 6. Second monthly data feedback

20 Individual services will receive feedback on their routinely collected data on alcohol care every two
21
22 months during their support phase. Data will be represented visually using images and or graphs
23
24 (Figure 3) and be fed back to nominated staff, including champions. Services will be asked for
25
26 feedback on the data representation and adaptations will be made as requested. Services will be
27
28 encouraged to discuss the results among staff, to see if there are ways to further improve alcohol
29
30 screening and treatment rates.
31
32
33
34

35 (Insert Figure 3 about here)
36
37
38
39

40 7. Phone conferences

41 Second-monthly phone conferences will be organised for service champions. These conferences
42
43 will provide the opportunity for ACCHSs to network nationally. The champions will be split into two
44
45 groups for the phone conferences, based on remoteness. During teleconferences, champions can
46
47 discuss their data feedback, progress, successes, difficulties, helpful tools, resources or
48
49 approaches.
50
51
52
53

54 8. Online platform

55 A password-protected web portal will allow ACCHS staff to access and share current evidence,
56
57 culturally appropriate resources, and to network. It will include a discussion board. Short videos,
58
59 training presentation slides, and clinical protocols will be uploaded by project staff.
60

Data collection

Qualitative data

Qualitative data will be collected from ACCHSs at the start of the early support arm. The data will help inform the support model. Structured phone interviews will be conducted with approximately five staff members from each ACCHS in the early support arm, with the aim of a total of fifty. Champions and/or key staff will be approached to assist with recruiting interviewees.

Alcohol can be sensitive to discuss due to cultural protocols such as kinship/family systems, gender or age, shame (embarrassment) or community and social acceptance of alcohol [37-39]. Therefore, the interview questions will be framed using a strengths-based, capacity-building approach [40]. Interview questions will include: approaches to make it easier to talk about alcohol, treatment around alcohol, skills and knowledge needed to provide quality alcohol care, new ways of helping people who struggle with alcohol, other successful programs that could be used as a model for alcohol care, and ideas for improvement in alcohol care.

Interviews will be conducted by two Indigenous staff with experience working with ACCHSs and conducting interviews. One interviewer will facilitate the interview while the other will live-transcribe. The interviewers will compare and discuss notes after each interview. Memos will also be written by the lead author (KH) on each interview.

Quantitative data

Non-identifiable data on episodes of screening and alcohol care and related variables (see below) will be extracted from the Communicare database of each ACCHS on the 28th day of every second month throughout the 5-year trial (Figure 4). The baseline extraction will include data for 12 months before the trial starts. Participating services use a Structured Query Language (SQL) report developed for this project to extract data, then will send data to the project team. Data will include AUDIT-C responses, and the client's drinking status as perceived by a health professional ('Non-drinker', 'Within safe drinking limits' or 'Unsafe - needs intervention'); record of alcohol brief

1
2 intervention, counselling, and medicines prescribed for relapse prevention (i.e. acamprostate,
3
4 naltrexone or disulfiram).
5
6
7

8 (Insert Figure 4 about here)
9
10
11

12 Other data extracted will include age, gender, last date the client was seen, and biological markers
13 which may be affected by alcohol consumption (BP, HbA1C and GGT).
14
15
16
17

18 A spreadsheet will track dates when key elements of support are provided to each service.
19
20
21
22

23 Service retention and withdrawal

24 Regular contact will be made with services during their support phase through second monthly
25 teleconferences (by KC and often KH), and also for the purposes of data extraction (by BH). Every
26 effort will be made to address any concerns or suggestions, and to minimise any burden of
27 participation on the services. However, services may withdraw from the study, for any reason and
28 at any time.
29
30
31
32
33
34
35
36
37

38 Data storage and confidentiality

39 Data, and study-related material will be stored securely in a University of Sydney drive only
40 accessible by the research team. To protect confidentiality, identification numbers rather than
41 names are used for services in the data set and reporting. Client names are never provided to the
42 research team. Investigators involved in data analysis, and selected administrative staff will be
43 granted access to study data.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Analysis

Qualitative

Two independent analyses of the qualitative data will be conducted: analysis of the memos and of the transcripts. This complementary analytical strategy aims to enhance examination of the raw data in the formation of key concepts [41].

Interview transcripts and memos will each be imported into the qualitative software, NVivo (Version 11). Memos will be analysed by the lead interviewer (KH). Transcripts from the structured interviews will be analysed by an independent research associate to produce key themes. This involves the interpretation of descriptive data to explain the meanings of the interviewees' responses [42]. Each data set will be coded separately using a process of constant comparison [42]. This will involve coding and organising likened data into categories along with a comparison and interpretation of emerging themes across all transcripts and memos [43]. A team of relevant experts will meet to discuss both analyses and find consensus on key themes and sub-themes. These key themes and findings will be described.

Quantitative

Only the data on Indigenous Australian clients age 16+ years who have attended a participating ACCHS in the past 12 months will be included in analysis to assess:

1. The number of clients who are screened using AUDIT-C
2. The number of clients identified with unhealthy alcohol use
3. The number of clients who are offered treatment, including advice/education or counselling, relapse prevention medicines

We will calculate AUDIT-C screening rates before and after support is provided; and records of treatment provided. These data will be compared between the two study arms.

Characteristics of ACCHSs, such as number of clients, will be compared descriptively between the early- and late-support services. Characteristics that display major imbalance between arms will be considered as adjustment factors in outcome analyses.

1
2
3
4 Multi-level logistic regression will then be performed to assess whether rates of screening and
5
6 treatment provision differ between early- and late-support services. The multi-level logistic
7
8 regression model accounts for episodes of screening being nested within clients, who are
9
10 themselves nested within the services they attend. We will perform unadjusted analyses, as well as
11
12 adjusting for characteristics that are unbalanced between study arms. We will use statistical
13
14 packages, SPSS for descriptive analyses and R for multi-level modelling. As data is collected as
15
16 part of routine clinical activity, missing data is likely to be non-random, as such multiple-imputation
17
18 will not be performed.
19
20
21
22

23 We will assess if clients are more likely to be screened and offered treatment during periods when
24
25 their service is being supported. A secondary analysis using multi-level regressions, will assess if
26
27 the support offered is associated with changes in the recorded prevalence of unhealthy drinking
28
29 (using AUDIT-C) or changes in biological markers that can be affected by alcohol (GGT, HbA1c
30
31 and BP).
32
33
34

35 **Ethical approvals**

36
37 Ethical approval has been obtained from eight ethics committees: The Aboriginal Health and
38
39 Medical Research Council of New South Wales (1217/16); Central Australian Human Research
40
41 Ethics Committee (CA-17-2842); Northern Territory Department of Health and Menzies School of
42
43 Health Research (2017-2737); Central Queensland Hospital and Health Service (17/QCQ/9); Far
44
45 North Queensland (17/QCH/45-1143); Aboriginal Health Research Ethics Committee, South
46
47 Australia (04-16-694); St Vincent's Hospital (Melbourne) Human Research Ethics Committee (LRR
48
49 036/17); and Western Australian Aboriginal Health Ethics Committee (779).
50
51
52
53

54 As there are minimal foreseeable risks in this study, there will not be an independent committee
55
56 monitoring conduct of the trial, data or adverse events. Feedback from services will be provided to
57
58 the investigators and adaptations made as necessary.
59
60

Patient and public involvement in the research

This trial was suggested by the Aboriginal Health Council SA, the umbrella organisation for South Australian community controlled health services. Service participation in the trial must be approved by the Board of each community-controlled health service. The Board is recognised as representing patients and community in such decisions. As described above, service staff will be consulted throughout their support phase on how the project can best support them. Results will be fed back bimonthly to services in an accessible manner for all staff and Board members, and services will have opportunity to provide comment on draft outcome reports before publication.

Dissemination of findings

As described above, results will be reported directly to participating ACCHSs. Results will then be disseminated via peer-reviewed publications and conference presentations. Publications will be led by study investigators, research students or staff supported by the investigators. The resources developed through this trial will also be made freely available electronically at the end of the study period to support other health services.

Data sharing

It is not possible to make the dataset publicly available because of ethical constraints. Alcohol is a sensitive issue, and the data belongs jointly to the 22 services who take part. For the main outcome report, statistical code used to analyse data will be made publicly available.

Authorship policy

All grant holders, and those involved in study conception and design, will co-author the main outcome piece. Further articles may be produced based on sub-analyses, or on ancillary research questions. Those papers will be authored by those directly involved in those research questions. Acknowledgement will be given to individuals involved in the design of the main paper.

Protocol amendments

The trial's registration data is shown at Table 2 (ACTRN12618001892202). If any protocol amendments are necessary, these be agreed on by study authors, and where appropriate, participating services. Then they will be registered with the Australian and New Zealand Clinical Trials Registry.

Table 2. WHO trial registration data

Data category	Information
Primary registry and trial identification number	Australia New Zealand Clinical Trials Registry: ACTRN12618001892202
Date of registration in primary registry	2018-11-21
Secondary identifying numbers	APP1105339
Sources of monetary or material support	National Health and Medical Research Council (NHMRC; Australia)
Primary sponsor	The University of Sydney
Secondary sponsor	Royal Prince Alfred Hospital
Contact for public and scientific queries	Kate Conigrave, MBBS, FACHAM, FAFPHM, PhD kate.conigrave@sydney.edu.au
Public title	Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: a cluster randomised controlled trial
Scientific title	Increasing uptake of evidence-based management of unhealthy alcohol use in Aboriginal primary health care services: a cluster randomised controlled trial
Counties of recruitment	Australia
Health condition(s) or problem(s) studied	Hazardous alcohol use; Alcohol use disorders

Data category	Information
Interventions	Health service support (including training, sharing learning between services); regular data feedback
Key inclusion or exclusion criteria	<p>Health services:</p> <ol style="list-style-type: none"> 1. are Aboriginal Community Controlled Health services 2. deliver care to at least 1000 unique clients annually 3. use 'Communicare' as their practice software <p>Data from clients 16 years and older are eligible for extraction</p>
Study type	Interventional; Allocation: randomised; Primary purpose: prevention; Cluster randomised trial
Date of first enrolment	28/10/2016
Target sample size	22 services
Recruitment status	Complete
Primary outcomes	AUDIT-C screening rate
Key secondary outcomes	Brief intervention for alcohol rate

DISCUSSION

To our knowledge, this is the first large-scale randomised trial testing whether external support can enhance uptake of evidence-based alcohol care in services for Indigenous peoples. This study will add knowledge in the field of screening, early intervention and treatment for Indigenous peoples of Australia and inform future research and policy development. The findings are also likely to be relevant for Indigenous peoples internationally who have similar experiences of colonisation and inter-generational trauma. The research will also have relevance for non-Indigenous health services.

The model of support is designed to be culturally appropriate and collaborative, and tailored to individual service needs. The model is based on the use of champions within services, and feedback of routinely collected data, and so has potential to be sustainable, allowing for continuing quality improvement. The model also has potential to be scaled up for longer-term support of ACCHSs Australia-wide.

Acknowledgements

This work was supported by the NHMRC funding through a Project Grant (#1105339); a Centre of Research Excellence in Indigenous Health and Alcohol (#1117198); and a Practitioner Fellowship for K. Conigrave (#1117582). The funding body had no contribution to study design, writing of report, or in the decision to submit this report for publication; nor will they influence the submission of future reports. Thanks to Dr David Scrimgeour and to the Aboriginal Health Council of South Australia for suggesting this study. Also to Professor Sandra Eades, Professor Robert Sanson-Fisher and Mr Paul Ishiguchi for advice on study design and management.

Authors' contributions

KH refined the protocol for cultural appropriateness, drafted the protocol report; reviewed literature, recruited services, and will play a key role in training, qualitative data collection and qualitative analysis. KC, PH, NH, RI, KL conceived the study design. SW, NH assisted with ensuring design was culturally appropriate; KC,PH,RI, provide clinical expertise; BH and DJ provided guidance on

1
2 Communicare use and data extraction and ACCHS support; BH assisted with service recruitment
3
4 leads data extraction, and facilitates service liaison. TD developed the analysis plan, including
5
6 power analyses, and provides ongoing advice. JC is responsible for merging and curating the data,
7
8 and conducting t_1 quantitative analysis. KC, PH, RI, DG, TD, KL, SW, DJ are grant holders. All
9
10 grant holders are on the project steering committee; all authors contributed to the development of
11
12 the study protocol and approved this manuscript.
13
14
15

16 **Declaration of interests**

17
18 The principle investigators have no financial or other competing interests.
19
20
21

22 **Trial Sponsor**

23
24 The University of Sydney, NSW 2006, Australia and Sydney Local Health District
25
26
27
28

29 **Word Count:** 3396 (excluding tables, and acknowledgements onwards)
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. GBD 2016 Risk Factors Collaborators, *Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016*. Global Health Metrics, 2016. **Vol 390 September 16, 2017**.
2. Kirmayer, L.J., G.M. Brass, and C.L. Tait, *The mental health of Aboriginal peoples: transformations of identity and community*. Canadian Journal of Psychiatry, 2000. **45(7)**: p. 607-16.
3. Australian Bureau of Statistics/Australian Institute of Health and Welfare, *The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples*. 1999, ABS: Canberra.
4. Australian Institute of Health and Welfare, *Substance use among Aboriginal and Torres Strait Islander people*. 2011, Canberra: Australian Institute of Health and Welfare.
5. Australian Institute of Health and Welfare, *Aboriginal and Torres Strait Islander health performance framework, 2008 report: detailed analyses*. Cat. no. IHW 22. 2008, Canberra: AIHW.
6. Eckermann, A.-K., T. Dowd, and E. Chong, *Binan Goonj: bridging cultures in Aboriginal health*. 2010: Elsevier Australia.
7. Kaner, E.F.S., et al., *The effectiveness of brief alcohol interventions in primary care settings: a systematic review*. Drug and Alcohol Review, 2009. **28(3)**: p. 301-323.
8. Haber, P., et al., *Guidelines for the treatment of alcohol problems*. 2009, Canberra: Australian Government Department of Health and Ageing.
9. Chapman, C., et al., *Delay to first treatment contact for alcohol use disorder*. Drug and alcohol dependence, 2015. **147**: p. 116-121.
10. Solberg, L.I., M.V. Maciosek, and N.M. Edwards, *Primary care intervention to reduce alcohol misuse: ranking its health impact and cost effectiveness*. American Journal of Preventive Medicine, 2008. **34(2)**: p. 143-152.
11. World Health Organisation, *ICD-11 for mortality and morbidity statistics (ICD-11 MMS)* June 18 2018 ed. 2018: World Health Organisation.
12. Clifford, A., A. Shakeshaft, and C. Deans, *How and when health-care practitioners in Aboriginal Community Controlled Health Services deliver alcohol screening and brief intervention, and why they don't: A qualitative study*. Drug and Alcohol Review, 2012. **31(1)**: p. 13-19.
13. National Health and Medical Research Council, *Australian guidelines to reduce health risks from drinking alcohol*. 2009, Canberra, Australia: Commonwealth of Australia.
14. Reid, A.L.A., et al., *General practitioners' detection of patients with high alcohol intake*. British Medical Journal, 1986. **293**: p. 735-737.
15. d'Abbs, P., et al., *The Grog Mob: lessons from an evaluation of a multi-disciplinary alcohol intervention for Aboriginal clients*. Australian and New Zealand Journal of Public Health, 2013. **37(5)**: p. 450-456.
16. Campbell, M., J. Hunt, and AHMRC, *Aboriginal communities improving Aboriginal health: An evidence review on the contribution of Aboriginal Community controlled Health Services to improving Aboriginal health*. 2015, Sydney: Aboriginal Health and Medical Research Council, NSW.
17. Clifford, A., A. Shakeshaft, and C. Deans, *Training and tailored outreach support to improve alcohol screening and brief intervention in Aboriginal Community Controlled Health Services*. Drug and Alcohol Review, 2013. **32(1)**: p. 72-79.
18. Australian Institute of Health and Welfare, *National key performance indicators for Aboriginal and Torres Strait Islander primary health care First national results June 2012 to June 2013*. 2018.
19. Bradley, K., et al., *AUDIT-C as a brief screen for alcohol misuse in primary care*. Alcoholism: Clinical and Experimental Research, 2007. **31**: p. 1208-17.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
20. Islam, M.M., et al., *Standardised alcohol screening in primary health care services targeting Aboriginal and Torres Strait Islander peoples in Australia*. *Addiction Science & Clinical Practice*, 2018. **13**:5.
21. Gray, D., et al., *Barriers and enablers to the provision of alcohol treatment among Aboriginal Australians: A thematic review of five research projects*. *Drug and Alcohol Review*, 2014.
22. Calabria, B., et al., *Identifying Aboriginal-specific AUDIT-C and AUDIT-3 cutoff scores for at-risk, high-risk, and likely dependent drinkers using measures of agreement with the 10-item Alcohol Use Disorders Identification Test*. *Addiction Science & Clinical Practice*, 2014. **9**(1): p. 17.
23. Australian Institute of Health and Welfare, *AIHW National Key Performance Indicators Database User guide reporting period ending 30 June 2017*. 2017.
24. Department of Health and Ageing, *Alcohol Treatment Guidelines for Indigenous Australians*. 2007, Commonwealth of Australia: Canberra.
25. National Health and Medical Research Council, *The NHMRC Road Map II: A strategic framework for improving the health of Aboriginal and Torres Strait Islander people through research*. 2010.
26. Australian Bureau of Statistics, *1216.0 - Australian Standard Geographical Classification (ASGC) - 2006* 2006.
27. Australian Bureau of Statistics, *Census of Population and Housing: Characteristics of Aboriginal and Torres Strait Islander Australians, 2011* 2012, Canberra: ABS.
28. Panaretto, K., et al., *Evaluating performance of and organisational capacity to deliver brief interventions in Aboriginal and Torres Strait Islander medical services*. *Australian and New Zealand journal of public health*, 2010. **34**(1): p. 38-44.
29. Chikritzhs, T. and M. Brady, *Fact or fiction? A critique of the National Aboriginal and Torres Strait Islander Social Survey 2002*. *Drug and Alcohol Review*, 2006. **25**(3): p. 277-287.
30. Britt, H., et al., *General practice in Australia, health priorities and policy 1998 to 2008*. General practice series no. 24; Cat. no. GEP 24. 2009, Canberra: AIHW.
31. Sanatinia, R., et al., *Brief intervention for alcohol misuse in people attending sexual health clinics: study protocol for a randomized controlled trial*. *Trials*, 2012. **13**(1): p. 1-8.
32. Coulton, S., et al., *Screening and brief interventions for hazardous alcohol use in accident and emergency departments: a randomised controlled trial protocol*. *BMC health services research*, 2009. **9**(1): p. 114.
33. Carey M, B.H., Sanson-Fisher R, *The cycle of change: implementing best-evidence clinical practice*. *International Journal for Quality in Health Care*, 2009. **21**(1): p. 37-43.
34. Kowalyszyn, M. and A. Kelly, *Family functioning, alcohol expectancies and alcohol-related problems in a remote Aboriginal Australian community: a preliminary psychometric validation study*. *Drug and Alcohol Review*, 2003. **22**(1): p. 53-59.
35. Lee, K., et al., *Handbook for Aboriginal Alcohol and Drug Work*. 2012, Sydney, NSW: University of Sydney.
36. Haber, P., et al., *Quick reference guide to the treatment of alcohol problems: companion document to the guidelines for the treatment of alcohol problems*. 2009, Prepared for the Australian Government Commonwealth Department of Health and Ageing: Canberra. p. 9.
37. Hirsch, A., et al., *Every door closed: Barriers facing parents with criminal records*. 2002, Washington: Community Legal Services, Inc.
38. Ministerial Council on Drug Strategy, *National Drug Strategy Aboriginal and Torres Strait Islander Peoples Complementary Action Plan 2003-2009 (Background Paper)*. 2006, Commonwealth of Australia: Canberra.
39. Sibthorpe BM, et al., *The demise of a planned randomised controlled trial in an urban Aboriginal medical service*. *Medical Journal of Australia*, 2002. **176**(6): p. 248-9.

- 1
2 40. NSW Health Department, *A Framework for Building Capacity to Improve Health*. 2001.
3 41. Melanie Birks, Y.C., Karen Francis, *Memoing in qualitative research. Probing data and*
4 *processes*. Journal of Research in Nursing, 2008. **13**(1): p. 68–75.
5 42. Morse, J.M. and P.A. Field, *Qualitative research methods for health professionals*. 1995.
6 **2nd edition**: p. 254
7 43. Glaser, B. and A. Strauss, *The discovery of grounded theory: strategies for qualitative*
8 *research*. Chicago: Aldine Publishing Company, 1967.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2 **Figure Legends**
3
4

5 Figure 1. Project principles – embedding mainstream evidence into a cultural care approach
6


7 Figure 2. Flow diagram for the trial
8

9 Figure 3. Three elements used to feedback alcohol screening data to ACCHSs
10


11 Figure 4: Project Timeline: SPIRIT schedule of enrolment, interventions, and assessments for the
12
13
14 trial
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




review only



1. Are you meeting your AUDIT-C screening goal?




2. How many clients your service is screening



Screening rate over 12 months (out of clients aged 16+ who have attended in the past year)

3. How is your AUDIT-C screening rate going over time?



Screening rate for each 2-month period

Figure 4: Project Timeline: SPIRIT schedule of enrolment, interventions, and assessments for the trial

Study period							
	Enrolment	Allocation	Post-allocation				
TIMEPOINT	<i>t</i> ₋₁ (Feb 16) Oct 2016 to Jun 2017	16/06/17	<i>t</i> ₀ 29/8/17 Year 1	<i>t</i> ₁ 28/8/18 Year 2	<i>t</i> ₂ 14/8/19 Year 3	<i>t</i> ₃ 13/8/20 Year 4	Close out 28/4/21
ENROLMENT:							
Eligibility screen	X						
Informed consent	X						
Allocation		X					
INTERVENTIONS:							
Early support services							
Late support services (wait-list control)							
ASSESSMENTS:							
Baseline/outcome variables Retrospectively collected for 2-monthly periods [†] from Feb 2016 to Feb 2021: AUDIT-C screening rate; provision of brief interventions [‡] , counselling; prescriptions for acamprosate, naltrexone, disulfiram; AUDIT-C results; systolic BP; GGT; HbA1c [§]	X	X	X	X	X	X	X

*Data will be retrospectively extracted for the 12-month period before the start of the support (the intervention). All data used in this study are routinely collected clinical data, extracted from the practice software ('Communicare')

[†] Data will be extracted on the 28th day of every second month.

The first census date (*t*₁) is one year after the start of the intervention; *t*₂₋₄ are other census points.

[‡] Unhealthy alcohol use = hazardous consumption or alcohol use disorders

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

§ Blood test results (GGT, HbA1c) are only available when these have been routinely conducted
ªActive support phase
¸Maintenance support phase

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only



THE UNIVERSITY OF
SYDNEY



Health
Sydney
Local Health District

Beth Hummerston
Project Officer

Aboriginal Health Council of South Australia

Kristie Harrison Project Coordinator / PhD Candidate
Sydney Medical School, University of Sydney

Kate Conigrave FChAM, FAFPHM, PhD
Senior Staff Specialist, Royal Prince Alfred Hospital
and Professor, Addiction Medicine, University of Sydney

[DATE]

name, CEO
organisation
address

Dear <Name>,

Re: Opportunity for your service to be supported further around alcohol management - a whole of service approach.

On behalf of our project team, I am excited to write to you to regarding an opportunity to take part in a national project. The project's goal is to make it easier for services to put in place evidence-based management of unhealthy alcohol use.

This project is the first of its kind in supporting Aboriginal & Torres Strait Islander (Indigenous) primary care services in making use of the full range of alcohol management approaches within their services.

We have recently been awarded an NHMRC grant for five years to undertake this project and to evaluate how well this support works. The project team will support services to refine their system-wide approaches to caring for individuals with unhealthy alcohol use based to their own service needs and on best evidence. There will also be sharing of learnings between services.

We know that alcohol can have very harmful effects on our communities and also that drinking even a little over recommended limits can increase the chance of cancers and other diseases. Taking a whole of service approach, which is critical to Indigenous values in addressing health issues, can have greater positive outcomes for patients and communities.

Please find attached a one page overview for more information about the project and the project team.

If you would like to discuss further please do not hesitate to give me or Kate Conigrave a call.

Warm regards,

Beth Hummerston
Project Officer

Kate Conigrave
Senior Staff Specialist and Professor

Kristie Harrison
Aboriginal Project Coordinator

[contact details provided for each signatory: land line, mobile and email address]



Prof Kate Conigrave
Drug Health Services, RPA Hospital
Missenden Rd
Camperdown NSW 2050
Email: kate.conigrave@sydney.edu.au Ph XXXXXXXX

Project: “Supporting Indigenous primary care services to reduce the harms from alcohol”
Information sheet: *This is for you to keep*

Researchers: Kate Conigrave, Paul Haber, Noel Hayman, Kylie Lee, Rowena Ivers, Tim Dobbins, Dennis Gray, David Johnson, Scott Wilson

Institutions: Sydney and Curtin Universities; Inala Indigenous Health Service; Royal Prince Alfred Hospital; Illawarra Aboriginal Medical Service; University of NSW; Aboriginal Health Council SA and Aboriginal Drug and Alcohol Council SA.

Funding: NHMRC (Project Grant, started June 2016).

Why does this research need to be done?

- Drinking problems have a big impact on families and communities. Also, people who drink even a little above recommended limits can have a greater chance of cancer and other medical conditions.
- In primary care services, unhealthy drinking is not addressed as often as smoking. Health staff may feel less comfortable in talking about alcohol and less confident in using alcohol treatments (like medicines to help a person stay dry, or to treat withdrawal).
- Treatments for unhealthy drinking can be used in primary care, and have been shown to be effective in improving health. They are part of national alcohol treatment guidelines.

How is this research going to be done?

- We will test ways to support Aboriginal and Torres Strait Islander (Indigenous) primary care services to do the best they can to help people with unhealthy alcohol use. Approaches will be led by the services and guided by the evidence base.
- Twenty two primary care services around Australia will be invited to take part. To be involved, services will have: 1000+ clients in a 12-month period and use Communicare. Services can pull out at any time.
- Half the services (randomly selected) will receive support over two years to improve the way their service works with alcohol use – ‘initial support’ services. The other 11 services will wait to get this support at the end of the study – ‘wait-control’ services.
- The 11 ‘initial support’ services will each choose two project ‘champions’ e.g. a clinician and a manager. The project coordinator will support those champions and their services to find and address barriers to addressing unhealthy drinking.
- To help this process, the project staff will interview up to five staff members from each service (including the champions) about barriers to change, and opportunities to address these barriers.

Information sheet for services

- The representatives of the 'initial support' services will join forces and share ideas and experiences in service improvement through a face-to-face workshop and second monthly teleconferences over a two-year period.
- Practical support will be provided to services during the support phase, including educational resources, on-site staff training, support with refining Communicare and support for developing or adapting resources. Agreed expenses will be reimbursed up to \$9000 for 'initial support' services and \$3500 for 'wait-control' services.
- Each 'initial support' service will get regular (four times a year) feedback on how they are going based on their Communicare data: how often they screen for unhealthy alcohol use and how often they provide advice or treatment. De-identified data will be transferred to an agreed secure and confidential location.
- Results will be compared between 'initial support' and 'wait-control' services on how often screening is done and how often treatment is provided. Any changes in service-wide levels of drinking, blood pressure and liver blood tests will also be noted.

Storage and use of the data

The data will be stored at the Aboriginal Health Council SA (AHCSA) and at the University of Sydney. The data will be used to give feedback to each service on how they are going. Also reports on the overall study will be prepared for services and for publication.

Confidentiality

Any information given to the researchers will only be used for this research, and no one outside the project team will have access to the raw data. The information will not be given out to other people, except in summary reports as we describe in this information sheet. No staff member will be able to be identified in any summary report. Services will not be named and efforts will be made to avoid revealing the identity of the service in any way. Services will be given the opportunity to comment on publications.

Voluntary nature of this study

Services can choose if they would like to take part in this study. Also, services can withdraw at any time, and without affecting their relationship with the researchers.

Risks and benefits of taking part

- The study is designed to take as little time of service staff as possible, and to maximize the benefit to the services.
- Services who take part will be assisted to help their clients work towards a healthy approach to alcohol. Staff should gain skills, knowledge and confidence.
- The study should provide a model for how to support other Indigenous primary care services to give the best possible care for unhealthy drinking within their communities

Contacts

For further information, please contact Prof Kate Conigrave (details above) or Kristie Harrison on *[phone number]* or on *[email address]*

If you have any concerns or complaints about this study you can contact Kate or Kristie, or the Menzies Human Ethics Research Committee (ph 08 8946 8600 or email ethics@menzies.edu.au):



Prof Kate Conigrave
Drug Health Services, RPA Hospital
Missenden Rd
Camperdown NSW 2050

Email: kate.conigrave@sydney.edu.au Ph 02 XXXX XXXX

Project: “Supporting Indigenous primary care services to reduce the harms from alcohol”
Consent Form: *This means you can say NO*

Project: Supporting Indigenous primary care services to reduce the harms from alcohol

Researchers: Kate Conigrave, Paul Haber, Noel Hayman, Kylie Lee, Rowena Ivers, Tim Dobbins,
Dennis Gray, David Johnson, Scott Wilson

On behalf of **>Service Name<**, I freely give consent to participate in the above research project.

- I confirm that I have informed all relevant staff, and the Board of Directors about the project.
- I understand how the project will be conducted as described by members of the research team.
- I have received the project information sheet and have kept a copy of this at our service.
- I understand that our service can withdraw from the project at any time without reason and that this will not affect our relationship with the researchers.
- I consent to our service/staff:
 - Collaborating with the research team to develop a memorandum of understanding (MOU)
 - Committing to a whole of service approach for the project
 - Nominating two staff members (e.g. one managerial and one clinical) to champion the project
 - Participating in consultations, interviews, teleconferences and meetings to assist in the development and implementation of quality improvement approaches for our service.
- I authorise the extraction and transfer of de-identified patient data from **>Service Name<** Communicare system to researchers. I understand that these data will be kept secure in an agreed location.
- I understand that any information provided by staff of this service (e.g. in interviews or workshop) will be de-identified before being reported on publically and that the service will not be named in any publication.
- I confirm that I have had enough time to ask questions or request further information.

Consent form – Services-NT

CEO/Service representative Signature: _____ Date: _____ Time _____

Name: _____

Chairperson: Signature _____ Date: _____

Name: _____

Service address: _____

Phone: _____

Fax: _____

Researcher Signature: _____ Date: _____

Name: _____

Contacts: if you have any questions about this research please contact Kate Conigrave (details above) or Beth Hummerston via *[email address]* or *[phone number]*.

For peer review only



Prof Kate Conigrave
Drug Health Services, RPA Hospital
Missenden Rd
Camperdown NSW 2050
Email: kate.conigrave@sydney.edu.au Ph 02 XXXX XXXX

Project: "Supporting Indigenous primary care services to reduce the harms from alcohol"
This is for you to keep

Researchers: Kate Conigrave, Paul Haber, Noel Hayman, Kylie Lee, Rowena Ivers, Tim Dobbins, Dennis Gray, David Johnson, Scott Wilson

Institutions: Sydney and Curtin Universities; Inala Indigenous Health Service; Royal Prince Alfred Hospital; Illawarra Aboriginal Medical Service; University of NSW; Aboriginal Health Council SA and Aboriginal Drug and Alcohol Council SA.

Funding: NHMRC (Project Grant, started June 2016).

Why does this research need to be done?

- Drinking problems have a big impact on families and communities. Also, people who drink even a little above recommended limits can have a greater chance of cancer and other medical conditions.
- In primary care services, unhealthy drinking is not addressed as often as smoking. Health staff may feel less comfortable in talking about alcohol and less confident in using alcohol treatments (like medicines to help a person stay dry, or to treat withdrawal).
- Treatments for unhealthy drinking can be used in primary care, and have been shown to be effective in improving health. They are part of national alcohol treatment guidelines.

How is this research going to be done?

- Your service has agreed to take part in this study. The project will test ways of supporting Aboriginal and Torres Strait Islander (Indigenous) primary care services to prevent and treat alcohol problems. Approaches will be led by the services and guided by the evidence base.
- Twenty two primary care services around Australia are invited to take part.
- Half the services (randomly selected) will receive support over two years to improve the way their service works with alcohol use – 'initial support' services. The other 11 services will wait to get this support at the end of the study – 'wait-control' services. Your service was selected to receive the support early in the project.
- A range of practical support can be provided to all services. This can include educational resources, on-site staff training, support with refining Communicare and support for developing or adapting resources. Services themselves will have ideas on what support would be useful.
- We invite 2-5 staff members from each 'initial support' service to take part in an interview. This interview is to share ideas on what are challenges in preventing and caring for alcohol problems, and what types of support might be useful in making it easier. The interview can also cover things that are working well in the way your service works in relation to alcohol.
- You are invited to take part in that staff member interview and share your ideas with us. The interview should last about 45 minutes.

Information sheet for staff member interview

- We will take notes on these interviews, and then make a summary of what we have learned from speaking with staff of the 11 'initial support services'.

Use of the data

We will use the summary report from the interviews at a workshop attended by representatives of the 11 'initial support' services. The summary will help guide the discussion and allow sharing of ideas. It will also help guide the support we provide over the rest of the project. We will also use the information from the interviews and workshop to write a summary report to help other services around Australia. We would share that summary through conferences or a scientific publication.

Confidentiality

The report will only have summary data and we will not identify an individual in any report or discussion.. Sometimes we will quote what a staff member said, but we will not name them or their service. Care will be taken that no staff member or service will be able to be identified in any report.. Services will be given the opportunity to provide comment on publications.

It is your choice if you take part

It is your choice if you take part in this interview. You can withdraw at any time, and that is fine. If you want us to, we can take your data out of the study.

Risks and benefits of taking part?

- We hope that you will enjoy taking part and that you will find it helpful in reflecting on how your service is working on the issue of alcohol
- There is minimal risk in taking part, as the results of the interview are confidential and you are not identified in the summary report.
- The interview will help to inform what support your service and other support services get from the project team. This support should make it easier for your service to help clients to have a healthy approach to alcohol.
- The study should provide a model for how to support Indigenous primary care services to give the best possible care for unhealthy drinking within their communities.

Contacts

For further information, please contact Prof Kate Conigrave (details above) or Beth Hummerston via *[email address]* or *[phone number]*

If you have any concerns or complaints about this study you can contact Kate or Beth, or the Menzies Human Ethics Research Committee (ph 08 8946 8600 or email ethics@menzies.edu.au):

Consent for interview – Staff member



THE UNIVERSITY OF
SYDNEY

Prof Kate Conigrave FChAM, FAFPHM, PhD
Royal Prince Alfred Hospital
Missenden Rd,
Camperdown NSW 2050

Ph: 02 9515 8650 FAX: 02 9515 5779 Email: kate.conigrave@sydney.edu.au

Project: Supporting Indigenous primary care services to reduce the harms from alcohol

Consent for interview
“This means you can say NO”

Researchers: Kate Conigrave, Paul Haber, Noel Hayman, Kylie Lee, Rowena Ivers, Tim Dobbins,
Dennis Gray, David Johnson, Scott Wilson

I confirm that:

- I have received information about this research project.
- The research project has been explained to me and I fully understand why the research is being done and what I am being asked to do in it.
- I understand that I may stop taking part in this research interview at any stage.
- I understand that I may not directly benefit from taking part in the project.
- I understand that while information gained during the study may be published, I will not be identified in any way.

Signature: _____ Date: _____ Time: _____

Name of staff member: _____

I have explained the research project to the participant and believe that he/she understands what is involved.

Researcher's signature: _____ Date: _____

Name of researcher: _____

Contacts: if you have any questions about this research please contact Kate Conigrave (details above) or Beth Hummerston via beth.hummerston@ahcsa.org.au or (08) 8273-7200.

Reducing Harms from Alcohol

Alcohol Treatment Project - Communicare Indicators

Data extraction and storage

Communicare data is extracted by a series of 11 SQL reports. These reports are uploaded to the practice software at each site.

[details of how to send the data to University of Sydney omitted here for brevity]

The service name is not recorded on the data base. Instead a number from 1 to 22 is used to identify a folder for the data for each service.

Each patient within a service is identified by a Communicare ID. These numbers are not unique BETWEEN services, only within services. No name, address, date of birth or other identifying data is collected.

Key variables being extracted

1. Responses to each of the three questions within the clinical item *Check up;alcohol;AUDIT-C*

- Q1: How often do you have a drink containing alcohol?
- Q2: How many drinks containing alcohol do you have on a typical day when you are drinking?
- Q3: How often do you have six or more drinks on one occasion?

Information within each of these reports; Patient ID, Aboriginality, Age, Date the qualifier was recorded, the clinical item in which the qualifier was recorded, and the name of the qualifier and the qualifier response.

2. Drinking status extracted as Communicare qualifier *Alcohol consumption level*

- Status is recorded as 'Ex-drinker', 'Non-drinker', 'Unsafe – needs intervention', or, 'Within safe drinking limits'

Information within each of these reports includes: Patient ID, Age, Gender, Date the qualifier was recorded, clinical item in which the qualifier was recorded in.

3. Non pharmaceutical 'treatment' provided for unhealthy drinking:

Two relevant clinical items that capture alcohol 'treatment' (unless Communicare has been locally modified):

- ***Advice/education; alcohol;*** and
- ***Counselling; alcohol***

Information within each of these reports includes: Patient ID, Aboriginality, Age, Gender, Date the qualifier was recorded, and the clinical item in which the qualifier was recorded.

4. Alcohol relapse prevention medicines:

A list of scripts for alcohol relapse prevention meds (searching for both brand and generic names of the medicines acamprosate, naltrexone and disulfiram).

Information within each of these reports includes; Patient ID, Client status, Aboriginality, Age, Gender, Generic drug name, Prescription details, Prescription date

5. Biomedical results: GGT, systolic BP and HbA1C

Information within each of these reports; Patient ID, Age, Gender, Date the result was recorded, Clinical item the result was record in, qualifier name the result was recorded in, result.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	i
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	iv; Table 2 (p13)
	2b	All items from the World Health Organization Trial Registration Data Set	Table 2 (p13)
Protocol version	3	Date and version identifier	iv
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	i, 15
	5b	Name and contact information for the trial sponsor	15
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	i, 15

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 1 - 3
 4 rationale studies (published and unpublished) examining benefits and harms for each intervention

5

6 6b Explanation for choice of comparators 2

7

8 Objectives 7 Specific objectives or hypotheses 3

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
 11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 3

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 3
 17 be collected. Reference to where list of study sites can be obtained

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 4
 20 individuals who will perform the interventions (eg, surgeons, psychotherapists)

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 6 – 9; Figure 2 (p3)
 23 administered

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 12
 26 change in response to harms, participant request, or improving/worsening disease)

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 10
 29 (eg, drug tablet return, laboratory tests)

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial N/A

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
 35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 4
 36 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
 37 efficacy and harm outcomes is strongly recommended

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 6, Figures 2 (p3)
 41 participants. A schematic diagram is highly recommended (see Figure)

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	5
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	4
5				
6	Methods: Assignment of interventions (for controlled trials)			
7				
8	Allocation:			
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	5
11				
12				
13				
14				
15	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	5
16				
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	4-5
21				
22				
23	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	6
24				
25				
26		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
27				
28				
29				
30	Methods: Data collection, management, and analysis			
31				
32	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9-10
33				
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	10
39				
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	10
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11-12
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11-12
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation).	12
11				
12				
13				

14 **Methods: Monitoring**

15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed **It's mainly used where treatment can cause harms, here minimal risk**	12
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	10
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12
29				
30				
31				

32 **Ethics and dissemination**

33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	12
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4-5
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	5
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial. **do we need to mention data destroyed 7 years after last publication)?	10
8				
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
12				
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	13
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	13
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	13
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendices 1-4
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA
36				
37				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030909.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Aug-2019
Complete List of Authors:	Harrison, Kristie; The University of Sydney, Faculty of Medicine and Health Lee, KS; The University of Sydney, Faculty of Medicine and Health; La Trobe University, Centre for Alcohol Policy Research Dobbins, Timothy; University of New South Wales, School of Public Health and Community Medicine Wilson, Scott; Aboriginal Drug and Alcohol Council of South Australia, ; The University of Sydney, Faculty of Medicine and Health Hayman, Noel; Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care (Inala Indigenous Health Service); Griffith University, School of Medicine Ivers, Rowena; Illawarra Aboriginal Medical Service; The University of Sydney, Faculty of Medicine and Health Haber, Paul; University of Sydney - Camperdown and Darlington Campus, Discipline of Addiction medicine; Sydney Local Health District, Drug Health Services Conigrave, James; The University of Sydney, Faculty of Medicine and Health Johnson, David; Aboriginal Health Council of South Australia Hummerston, Beth; Aboriginal Health Council of South Australia, Gray, Dennis ; Curtin University Bentley Campus, National Drug Research Institute Conigrave, Katherine; University of Sydney, Sydney Medical School; Royal Prince Alfred Hospital, Drug Health Services
Primary Subject Heading:	Health services research
Secondary Subject Heading:	General practice / Family practice, Health services research, Public health, Evidence based practice, Addiction
Keywords:	Aboriginal, alcohol, screening, AUDIT-C, health services, PREVENTIVE MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7 **Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for**
8 **a cluster randomised controlled trial**
9
10

11
12
13
14 Kristie H Harrison¹

15
16 KS Kylie Lee^{2, 3}

17
18 Timothy Dobbins⁴

19
20 Scott Wilson^{5, 2}

21
22 Noel Hayman^{6, 7, 8}

23
24 Rowena Ivers^{9, 1}

25
26 Paul S Haber^{10, 2}

27
28 James H Conigrave²

29
30 David Johnson¹¹

31
32 Beth Hummerston¹¹

33
34 Dennis Gray¹²

35
36 Katherine M Conigrave^{10, 2}

37
38
39
40
41 ¹ The University of Sydney, Faculty of Medicine and Health, School of Public Health, NHMRC
42 Centre of Research Excellence in Indigenous Health and Alcohol; C39, University of Sydney,
43 New South Wales 2006 Australia
44
45

46
47 ² The University of Sydney, Faculty of Medicine and Health, Discipline of Addiction Medicine,
48 NHMRC Centre of Research Excellence in Indigenous Health and Alcohol; C39, University of
49 Sydney, New South Wales 2006 Australia
50
51

52
53
54 ³ La Trobe University, Centre for Alcohol Policy Research, Bundoora, Victoria 3083 Australia
55
56

1
2
3 ⁴ University of New South Wales, National Drug and Alcohol Research Centre, Kensington, New
4
5 South Wales 2052 Australia

6
7 ⁵ Aboriginal Drug and Alcohol Council Inc., 155 Holbrooks Rd, Underdale, South Australia 5032
8
9 Australia

10
11 ⁶ Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary
12
13 Health Care, PO Box 52, Inala, Queensland 4077 Australia

14
15 ⁷ Griffith University, School of Medicine, Parklands Drive, Southport, Queensland 4215 Australia

16
17 ⁸ University of Queensland, School of Medicine, St Lucia, Queensland 4072 Australia

18
19 ⁹ Illawarra Aboriginal Medical Service, 150 Church St, Wollongong, New South Wales 2500
20
21 Australia

22
23 ¹⁰ Sydney Local Health District, Royal Prince Alfred Hospital, Drug Health Services, Missenden
24
25 Rd, Camperdown, New South Wales 2050 Australia

26
27 ¹¹ Aboriginal Health Council of South Australia, 220 Franklin St, Adelaide, South Australia 5000
28
29 Australia

30
31 ¹² National Drug Research Institute, Curtin University, 7 Parker Place, Technology Park,
32
33 Bentley Western Australia 6102 Australia

34
35
36
37
38
39
40
41 Corresponding author

42
43 Kate Conigrave

44
45 Drug Health Services, Royal Prince Alfred Hospital

46
47 Missenden Road

48
49 Camperdown NSW 2050

50
51 Phone +61 2 9515 8650 Email: kate.conigrave@sydney.edu.au

ABSTRACT

Introduction

Indigenous peoples who have experienced colonisation or oppression can have a higher prevalence of alcohol-related harms. In Australia, Aboriginal Community Controlled Health Services (ACCHSs) offer culturally accessible care to Aboriginal and Torres Strait Islander (Indigenous) peoples. However there are many competing health, socio-economic and cultural client needs.

Methods and analysis

A randomised cluster wait-control trial will test the effectiveness of a model of tailored and collaborative support for ACCHSs in increasing use of alcohol screening (with AUDIT-C) and of treatment provision (brief intervention, counselling or relapse prevention medicines).

Setting: Twenty-two ACCHSs across Australia

Randomisation: Services were stratified by remoteness, then randomised into two groups. Half receive support soon after the trial starts (intervention or 'early support'); half receive support two years later (wait-control or 'late support').

The Support: Core support elements will be tailored to local needs and include: support to nominate two staff as champions for increasing alcohol care; a national training workshop and bi-monthly teleconferences for service champions to share knowledge; onsite training, and bi-monthly feedback on routinely collected data on screening and treatment provision.

Outcomes and analysis: Primary outcome is use of screening using AUDIT-C as routinely recorded on practice software. Secondary outcomes are recording of brief intervention, counselling, relapse prevention medicines; and blood pressure, gamma glutamyltransferase and HbA1c. Multi-level logistic regression will be used to test the effectiveness of support.

Ethics and dissemination

Approval was obtained from eight ethics committees (Aboriginal-specific where available): in New South Wales (#1217/16); Central Australia (#CA-17-2842); Northern Territory (# 2017-2737); Central Queensland (#17/QCQ/9); Far North Queensland (#17/QCH/45-1143); South Australia (#04-16-694); St Vincents Hospital (Melbourne; #LRR 036/17); and Western Australian (#779). Results will be disseminated through reports to ACCHSs, peer-reviewed publications and conferences.

Trial registration

Australian New Zealand Clinical Trials Registry (ACTRN12618001892202 Version 1) retrospectively registered 21/11/18.

Strengths and limitations of this study

- This large cluster randomised controlled trial provides the power to test whether a model of support for Aboriginal and Torres Strait Islander primary care services can increase rates of alcohol screening and treatment provision.
- The protocol has been designed to be compatible with cultural context and to integrate western knowledge with the expertise and holistic approaches of these services.
- The use of regular data feedback and nomination of service champions offers the services an opportunity to be involved in ongoing quality improvement on alcohol care.
- The resultant study will be able to use routinely collected outcome data but this relies on the accurate recording of screening and alcohol care provided to clients.

INTRODUCTION

Globally, alcohol is the leading cause of death and disease for all people between the ages of 15-49 [1]. Indigenous peoples dealing with colonisation and oppression can be at higher risk of mental illness and harms from alcohol [2]. In Australia, the proportion of Aboriginal and Torres Strait Islander (Indigenous) people who drink alcohol is less than non-Indigenous people [3]. However, Indigenous Australians are 2-8 times more likely to be hospitalised for alcohol-related conditions [4] and nine times more likely to die from alcohol-related harms [5]. This directly impacts on the health gap between Indigenous and non-Indigenous Australians [4]. These increased risks and harms from drinking can be related to experiences of trauma, grief, poverty and cultural dispossession, resulting in increased mental illness, trans-generational trauma and lower life expectancy [2, 4, 6]. The lack of community autonomy and access to culturally appropriate treatment services also contribute [4].

Early detection of unhealthy drinking (i.e. of hazardous, harmful or dependent alcohol use) [7, 8] plays a key role in reducing the overall burden of alcohol conditions, particularly before people develop health problems or social impacts such as incarceration related to alcohol use [9-11]. Internationally, alcohol screening and brief intervention approaches have been found to be cost-effective in reducing unhealthy drinking, particularly for those who are not dependent on alcohol [9, 12]. However across Australian primary care settings, screening and brief intervention for unhealthy drinking is not always standardised [13], informed by Australian National Health and Medical Research Council (NHMRC) drinking guidelines [14], or systematically conducted. It is estimated that 50-70% of people with unhealthy drinking go undetected in Australian primary care [15]. This percentage was the same (50-70% undetected) in four Indigenous primary care settings in Queensland, Australia (in 2001) [16]. Even when alcohol dependence is present, pharmacological treatments to reduce risk of relapse are not regularly prescribed in primary health care [17-19].

Culturally-specific health care services that are led and delivered by Indigenous peoples can have a key role in improving quality of healthcare and treatment access [20]. Aboriginal Community

1
2 Controlled Health Services (ACCHSs) provide accessible and culturally appropriate health care to
3
4 Indigenous communities across Australia. Each ACCHS has its own holistic-based service delivery
5
6 model for the communities that they serve [20]. As with mainstream (general population) services,
7
8 knowledge and practice of screening and brief intervention varies between and within Indigenous
9
10 primary care services [13, 21, 22]. Some ACCHSs have an alcohol and other drug (AOD) worker
11
12 or team, or links with external AOD specialists/services. Others may have no specific AOD
13
14 expertise and health practitioners may lack confidence in delivering alcohol care (i.e. screening,
15
16 brief intervention, counselling or medicines). Prior to 2017, the Australian government had asked
17
18 ACCHS staff to record clients' alcohol use as 'safe' or 'unsafe', 'non-drinker' or 'ex-drinker' [22].
19
20 However health practitioners may or may not have known current drinking guidelines or have
21
22 applied these to assess the risk.
23
24
25
26

27 To increase standardisation of alcohol screening in ACCHSs, in July 2017 the use of AUDIT-C (the
28
29 Alcohol Use Disorders Identification Test-Consumption) was added as a national key performance
30
31 indicator for ACCHSs [23]. AUDIT-C [24] is a 3-item screening tool, comprised of the first three
32
33 questions of the 10-item AUDIT [25]. This short form has been shown to have good sensitivity and
34
35 specificity in comparison to the full AUDIT [24]. Several studies suggest that AUDIT-C is valid in
36
37 Indigenous primary care settings, though further study into culturally appropriate delivery is
38
39 suggested [26-28].
40
41
42
43

44 Internationally, research suggests that support can help primary care services increase
45
46 implementation of alcohol screening and brief intervention [29] or provision of pharmacotherapies
47
48 for relapse prevention in alcohol dependence [19]. Support which is multi-faceted, and targets
49
50 several areas of a health service seems particularly promising [29]. For example the approach
51
52 may target not just doctors, but other professionals, clients and organisational systems [29].
53
54 Continuing quality improvement approaches may offer sustainable benefit, including in ACCHSs
55
56 [30]. However there have been very few studies of culturally-relevant support models for ACCHSs
57
58 in alcohol care [21, 30], with even fewer conducted by Indigenous researchers.
59
60

1
2 This paper outlines the trial protocol for testing if a model of support can assist ACCHSs to
3
4 integrate the mainstream evidence base on alcohol care with their own cultural and clinical
5
6 expertise. The use of an inactive control group can be challenging on ethical and partnership
7
8 grounds, particularly for vulnerable communities. In contrast, a wait-control design allows support
9
10 to be delivered to all participating ACCHSs.
11
12
13
14

15 **Aims**

16
17 This trial aims to assess if a model of tailored and collaborative support for ACCHSs can result in
18
19 increased uptake of evidence-based screening and treatment for unhealthy alcohol use (i.e.
20
21 drinking above recommended limits). This service-wide model of support will be designed to build
22
23 upon services' existing strengths (Figure 1).
24
25
26
27

28 (Insert Figure 1 about here)
29
30
31

32 **METHODS**

33 **Overview**

34
35 A cluster randomised trial will test the effectiveness of a model of tailored and collaborative support
36
37 to increase the use of AUDIT-C and evidence-based treatment in ACCHSs compared with care as
38
39 usual. Culturally relevant supports will be offered with the aim of increasing staff skills and capacity
40
41 to develop, refine and deliver systems for alcohol care. These supports will be based on current
42
43 evidence and be in-line with services' cultural-care practices. Twenty-two ACCHSs will be recruited
44
45 across Australia. Services will be randomised into two arms, an early support (intervention) and a
46
47 late support (wait-control) arm (Figure 2).
48
49
50
51

52
53 The support provided will contain eight core elements (Table 1), but be tailored, guided by
54
55 ACCHSs, to their individual needs, including needs by remoteness. It will also be underpinned by
56
57 current evidence, such as national alcohol treatment guidelines [10], Alcohol Treatment Guidelines
58
59 for Indigenous Australians [31] and national alcohol consumption guidelines [14]. The study
60

1
2 methods will be based on principles of conducting health research with Indigenous Australians
3
4 [32]. This includes Indigenous involvement and engagement, benefits for Indigenous peoples, and
5
6 led by Indigenous Australians.
7
8
9

10 The primary outcome will be routinely collected data on screening rates using AUDIT-C.
11
12 Secondary outcomes will include recorded delivery of brief intervention, counselling or prescribed
13
14 medicines to reduce relapse in alcohol dependence. We will also describe changes in reported
15
16 drinking and in biological measures that can be affected by drinking such as gamma
17
18 glutamyltransferase (GGT, a liver enzyme), [33], HbA1C [34] and systolic blood pressure (BP) [34].
19
20
21
22

23 **Participating services and eligibility**

24 Recruitment

25
26 This trial will recruit whole services (no clients will be recruited). ACCHSs across Australia will be
27
28 recruited based on expression of interest after circulation of study information to eligible services. A
29
30 mix of services will be approached (by KH, BH or KC) with a range of remoteness as determined
31
32 by the Australian Standard Geographical Classification – Remoteness Area (ASGC-RA) [35]. Both
33
34 verbal and written information will be shared. Face-to-face meetings will be offered to eligible
35
36 services. Indigenous project staff will be employed in recognition of their specialist skills and
37
38 knowledge of working with ACCHSs. Additional time will be factored into project timelines for
39
40 engaging with ACCHSs, including liaising with multiple key staff, follow-up conversations, and
41
42 knowledge translation of research documents.
43
44
45
46
47

48 Inclusion criteria

49 Services eligible for the trial will meet the following criteria:

- 50 1. Are an ACCHS
 - 51 2. Provide care to 1000+ clients per annum
 - 52 3. Use Communicare™ as their practice software
- 53
54
55
56
57
58
59
60

Exclusion criteria

Services will only be excluded if signed institutional consent forms are not returned before the close of recruitment. Data from clients aged 15 or under will not be extracted.

Consent

After written institutional consent is signed, a memorandum of understanding (MOU) will be negotiated by the senior investigator (KC) and lead author (KH) with each ACCHS. Staff participating in individual qualitative interviews will also provide informed consent. Further consent will be sought, following completion of the main trial, if the authors wish to perform ancillary studies using stored data.

Randomisation

ACCHSs will be categorised into three strata based on their remoteness using ASGC-RA [35]: 1) urban and inner regional; 2) outer regional and remote; 3) very remote. Service names will be replaced by consecutive numbers. Within each stratum, half the services will be randomised by a computer program into the early support arm and half into the late support arm. Randomisation will be conducted by an author (TD) who is blind to services' names.

Sample size

Sample size requirements were calculated using PASS [36]. Because larger numbers are needed to be able to determine increases in treatment provision than to demonstrate an increase in screening, the treatment provision outcome was used for sample size calculation. In an ACCHS of 1000+ clients per year, approximately 60% (n=600) are likely to be aged 16 years or older [37]. We estimate that 57% of clients (n=342) have likely been screened for alcohol use within 12 months [38] and at least 25% (n=86) of screened clients are likely to be drinking above NHMRC recommended limits [14, 39, 40]. In the late support arm, it is likely that 60% (n=51) of identified unhealthy drinkers will have an alcohol intervention recorded [38]. Assuming an Intra-cluster correlation coefficient (ICC) of 0.04 [41, 42], enrolling 10 early support services and 10 late support services will allow for an increase in treatment provision over a 12-month period of at least 13% in the early support services

1
2 to be detected (i.e. from 60% to 73%; 80% power and 2-sided significance of 0.05). We will enrol an
3
4 additional service in each arm to allow for the possibility of clusters dropping out of the study.
5
6 Accordingly, the target number of services to be enrolled is 22.
7
8
9

10 **The model of support**

11
12 ACCHSs will be acknowledged as the experts in cultural health care for Indigenous peoples in their
13
14 communities and Australia. The study also recognises the need for flexibility based on needs of
15
16 individual services and of the ACCHS sector as a specialist sector overall. Support approaches will
17
18 include the same core elements (Table 1). However, approaches will be tailored to the needs of
19
20 each ACCHS, for what works best for their service, clients and communities.
21
22
23

24 **Table 1. Eight core support elements***

26 27 28 29 30 31	1. Service champions	Services asked to nominate two representatives to act as advocates of alcohol care and links between the service and research team
32 33 34 35 36 37 38 39 40 41 42	2. National workshop	National capacity building workshop for service champions at the start of the support phase (and for early support services, a wrap-up feedback workshop at the end of the maintenance support phase)
43 44 45 46	3. Onsite training	Training will be offered to each ACCHS at their service
47 48 49 50 51 52 53 54 55 56 57	4. Resources/funding	Some resources (e.g. visual resources for brief intervention and clinical guidelines), will be given to services for free. Additional funding will be provided for the selection and purchase of further resources (e.g. FASD doll, standard drink cups).

5.	Practice software support	Support will be provided to services throughout the trial to facilitate the routine clinical use of alcohol-related items in the practice software.
6.	Data feedback	Individual service data will be fed back to each service every second month
7.	Phone conferences	Phone conferences will be held every second month between service champions and project team (including an addiction medicine physician). These will allow sharing of ideas and joint problem solving.
8.	Online platform	Further resources and information will be shared via a secure online platform.

*These eight core elements of support will be tailored to local service needs. Further detail on each element is provided in the body of the text.

The core support elements were designed based on evidence-based approaches for supporting implementation of alcohol care [21, 29]. The project team also drew on their experience working within (six authors) and with Aboriginal health services; and in health workforce development (nine authors). Advice was also received from ACCHS peak organisations and networks in NSW and SA, and from a research team conducting a quality improvement trial for ACCHSs on diabetes screening [43].

At the start of the early support phase, the support will be refined based on preliminary analysis of qualitative data from staff interviews and after feedback from the initial national workshop for early support service representatives. Tailoring and further minor refinement of support will occur during the trial, informed by service feedback.

Early support ('intervention') services will receive the support soon after the trial starts (one year of active support, one year maintenance phase). Late support (wait-control) services will receive the

1
2 same intervention elements two years after the start of the early-support phase. Due to the nature
3
4 of the intervention, it is not possible to blind participants or staff as to which services are receiving
5
6 support.
7
8
9

10 1. Identifying service champions

11
12 Each service will be asked to identify two staff representatives to work collaboratively with their
13
14 service staff and the research team on increasing alcohol care. Services will be asked to consider
15
16 nominating a clinician, Aboriginal health professional and/or an individual from management.
17

18
19 Service champions will be invited to attend an initial national face-to-face workshop, and second-
20
21 monthly teleconferences. These meetings will ensure that support approaches are in line with the
22
23 values of each ACCHS, and will allow sharing of expertise and initiatives. Champions will be key
24
25 in highlighting the potential benefits of change in their service and will encourage service staff to
26
27 discuss their second monthly data feedback, and to address any key barriers to change [44].
28
29
30

31 2. Workshops

32
33 A national workshop will be held at the beginning of each support phase to bring champions from
34
35 those services together for capacity building and networking. Feedback will be obtained from
36
37 champions about pre- and post-workshop knowledge, training preferences, priority areas for
38
39 support and useful resources. Key presentations from workshops will be video-recorded and
40
41 made available via a password-protected website.
42
43
44
45

46 A wrap-up workshop will be organised for early support service champions (only) at the end of
47
48 their support phase. Opportunities will be provided for service champions to provide verbal and
49
50 written feedback on support, to discuss continuing quality improvement approaches and to
51
52 network. Study results to that point will be discussed.
53
54
55
56
57
58
59
60

3. Onsite training

Training will be offered at each service for all staff, with maximum duration of two days. Core elements will include screening, alcohol and the body, brief intervention and treatment approaches, including relapse prevention medicines. Due to the individuality of each service, flexibility will be given to allow inclusion of other (alcohol-related) training topics. The training will be co-facilitated by an Addiction Specialist (KC) and an Aboriginal researcher with clinical background (KH) and will use culturally specific content and resources. Training content will be aligned with Indigenous protocols such as gender appropriateness, kinship systems and cultural obligations; such a family and community sharing, which at times can impact on substance use [27, 45]. Pre- and post-training feedback will be collected from participants.

4. Resources / Funding

The trial will provide several hard copy and electronic resources for free to services (i.e. the Handbook for Aboriginal Alcohol and Drug Work [46], Alcohol Awareness Kit [46] and Quick Reference Guide to the Treatment of Alcohol Problems [47]).

Each ACCHS will be provided with funding to purchase additional resources. Services can choose, in partnership with the chief investigators, how they spend their funding. The early support arm of the project will receive up to \$9,000 for resources. The late support arm will receive up to \$3,500. This is a reduced sum as they will have access to resources developed within the early support phase, so time and development costs will be less. Resources must be alcohol-related and may include additional training, conference attendance, education resources for staff or clients, funds for health promotion events or for local adaptation of resources.

5. Practice software support

A Communicare™ support officer will be available during the trial to support ACCHSs with the practice software. Some ACCHSs may choose to make modifications to Communicare™ to make alcohol 'clinical items' more accessible for staff. One example is adding AUDIT-C into the Aboriginal and Torres Strait Islander (Indigenous) health assessment ('Adult Health Check'),

1 which was not routine in standard versions of Communicare™ at the time of trial commencement.
2
3
4 AUDIT-C can also be added to other regular assessments such as: antenatal and the pre-consult
5
6 examination (i.e. routine observations and/screening by a nurse or Aboriginal health worker before
7
8 seeing the doctor). Services will also be provided with information about existing fields ('clinical
9
10 items') available on Communicare™ for recording episodes of alcohol care (education/advice; on-
11
12 site counselling), which can then be retrieved by data extraction.
13
14
15

16 6. Second monthly data feedback

17
18 Individual services will receive feedback on their routinely collected data on alcohol care every two
19
20 months during their support phase. Data will be represented visually using images and or graphs
21
22 (Figure 3) and be fed back to nominated staff, including champions. Services will be asked for
23
24 feedback on the data representation early in the support phase and adaptations will be made as
25
26 requested. Services will be encouraged to discuss the results among staff, to see if there are ways
27
28 to further improve alcohol screening and treatment rates.
29
30
31

32
33 (Insert Figure 3 about here)
34
35
36
37

38 7. Phone conferences

39
40 Second-monthly phone conferences will be organised for service champions. These will provide
41
42 the opportunity for ACCHSs to network nationally. The champions will be split into two groups for
43
44 the phone conferences, based on remoteness. During teleconferences, champions can discuss
45
46 their data feedback, progress, successes, difficulties, helpful tools, resources or approaches.
47
48
49

50 8. Online platform

51
52 A password-protected web portal will allow ACCHS staff to access and share current evidence,
53
54 culturally appropriate resources, and to network. It will include a discussion board. Short videos,
55
56 training presentation slides, and clinical protocols will be uploaded by project staff.
57
58
59
60

Data collection

Qualitative data

Qualitative data will be collected from ACCHSs at the start of the early support arm. The data will help inform the support model. Structured phone interviews will be conducted with approximately five staff members from each ACCHS in the early support arm, with the aim of a total of fifty. Champions and/or key staff will be approached to assist with recruiting interviewees.

Alcohol can be sensitive to discuss due to cultural protocols such as kinship/family systems, gender or age, shame (embarrassment) or community and social acceptance of alcohol [48-50]. Therefore, the interview questions will be framed using a strengths-based, capacity-building approach [51]. Interview questions will include: approaches to make it easier to talk about alcohol, treatment around alcohol, skills and knowledge needed to provide quality alcohol care, new ways of helping people who struggle with alcohol, other successful programs that could be used as a model for alcohol care, and ideas for improvement in alcohol care.

Interviews will be conducted by two Indigenous staff with experience working with ACCHSs and conducting interviews. One interviewer will facilitate the interview while the other will live-transcribe. The interviewers will compare and discuss notes after each interview. Memos will also be written by the lead author (KH) on each interview.

Quantitative data

Non-identifiable data on episodes of screening and alcohol care and related variables (see below) will be extracted from the Communicare™ database of each ACCHS on the 28th day of every second month throughout the 5-year trial (Figure 4). The baseline extraction will include data for 12 months before the trial starts. Participating services use Structured Query Language (SQL) queries developed for this project to extract routinely collected data. For every 2-month period a denominator sheet will be extracted which includes the date of the last visit for each client who has attended during that period and their gender and age. In addition the following variables will be extracted, each one linked to an individual client ID and the date the variable was recorded:

1
2 AUDIT-C responses; the clinicians' perception of the client's drinking status ('Ex-drinker', 'Non-
3 drinker', 'Within safe drinking limits' or 'Unsafe - needs intervention'); whether a brief intervention,
4 or a counselling session for alcohol use was provided; whether a relapse prevention medication
5 was prescribed (i.e. acamprosate, naltrexone or disulfiram); and if measured, a range of biological
6 markers which may be affected by alcohol consumption (BP, HbA1C and GGT).
7
8
9
10
11
12
13

14 (Insert Figure 4 about here)
15
16
17

18
19 A spreadsheet will track dates when key elements of support are provided to each service. Staff
20 numbers attending training and participating in teleconferences will be recorded.
21
22
23

24 Service retention and withdrawal 25

26
27 Regular contact will be made with services during their support phase through the second monthly
28 teleconferences (by KC and often KH), and for the purposes of data extraction (by BH). Effort will
29 be made to address any concerns or suggestions, and to minimise burden of participation on
30 services. However, services may withdraw from the study, for any reason and at any time.
31
32
33
34
35
36

37 Data storage and confidentiality 38

39
40 De-identified data will be sent to the project team every two months (by email or Cloudstor). Data
41 will be stored securely in a University of Sydney drive only accessible by relevant members of the
42 research team. Identification numbers rather than names are used for services in the data set and
43 in reporting. Data will stored for seven years after the last publication on the study.
44
45
46
47
48
49

50 **Analysis**

51 Qualitative 52

53
54 Two independent analyses of the qualitative data will be conducted: analysis of the memos and of
55 the transcripts. This complementary analytical strategy aims to enhance examination of the raw
56 data in the formation of key concepts [52].
57
58
59
60

1 Interview transcripts and memos will each be imported into the qualitative software, NVivo (Version
2 11). Memos will be analysed by the lead interviewer (KH). Transcripts from the structured
3
4 interviews will be analysed by an independent research associate to produce key themes. This
5
6 involves the interpretation of descriptive data to explain the meanings of the interviewees'
7
8 responses [53]. Each data set will be coded separately using a process of constant comparison
9
10 [53]. This will involve coding and organising likened data into categories along with a comparison
11
12 and interpretation of emerging themes across all transcripts and memos [54]. A team of relevant
13
14 experts will meet to discuss both analyses and find consensus on key themes and sub-themes.
15
16 These key themes and findings will be described.
17
18
19
20
21
22

23 Quantitative

24 Only the routinely collected data on Indigenous Australian clients aged 16+ years who have
25
26 attended a participating ACCHS in the past 12 months will be included in analysis to assess:

- 27 1. The odds of a client being screened using AUDIT-C at least once in any two month period (out
28
29 of those who attend in that period)
- 30 2. The odds of a client being recorded as receiving treatment for unhealthy alcohol use at the
31
32 ACCHS, including advice/education or counselling, relapse prevention medicines
- 33 3. The number of clients identified by ACCHS staff to have unhealthy alcohol use:
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

48 We will use statistical packages, SPSS for descriptive analyses and R for multi-level modelling.
49
50 Multi-level modelling will be used to account for clustering of observations under clients, who are
51
52 nested within services. We will assess if clients are more likely to be screened for risky alcohol-use
53
54 and provided with treatment if they are attending a service receiving support.
55
56
57
58

59 Two dummy variables will be constructed to indicate whether or not clients were screened with the
60
61 AUDIT-C during each 2-month data extraction period, or if they received treatment. These

1 variables will be used as outcomes in multi-level logistic regressions. As data is aggregated at bi-
2 monthly intervals, repetitive screenings within those two-monthly periods, will not influence the
3 modelled effect of the intervention. However, to ensure that the intervention is associated with
4 increased odds of appropriate screening, we will create a dummy variable indicating whether a
5 client has been screened in the previous 12 months, and use this variable as the outcome in a
6 multilevel logistic regression.
7
8
9
10
11
12
13
14
15

16 Characteristics of ACCHSs, such as number of clients, will be compared descriptively between the
17 early- and late-support services. Characteristics that display major imbalance between arms will be
18 considered as adjustment factors in outcome analyses. As data is collected as part of routine
19 clinical activity, missing data is likely to be non-random, as such multiple-imputation will not be
20 performed.
21
22
23
24
25
26
27
28

29 All analyses will be repeated for the maintenance phase of the study to see if study effects
30 attenuate or strengthen over time. The analysis will also be repeated after the late support services
31 have received support, to see if any effect on use of screening or treatment can be replicated
32
33
34
35
36
37

38 If a significant effect of the support on alcohol care outcomes is demonstrated, a secondary
39 analysis will examine the elements of support which were most effective, and whether the effect of
40 support changed over time during a support phase. Potential change in client health indicators over
41 time (AUDIT-C scores, GGT, HbA1C, BP) will be examined in relation to support provision.
42
43
44
45
46
47

48 **Ethical approvals**

49 Ethical approval has been obtained from eight ethics committees: The Aboriginal Health and
50 Medical Research Council of New South Wales (1217/16); Central Australian Human Research
51 Ethics Committee (CA-17-2842); Northern Territory Department of Health and Menzies School of
52 Health Research (2017-2737); Central Queensland Hospital and Health Service (17/QCQ/9); Far
53 North Queensland (17/QCH/45-1143); Aboriginal Health Research Ethics Committee, South
54
55
56
57
58
59
60

1
2 Australia (04-16-694); St Vincent's Hospital (Melbourne) Human Research Ethics Committee (LRR
3
4 036/17); and Western Australian Aboriginal Health Ethics Committee (779).
5
6
7

8 As there are minimal foreseeable risks in this study, there will not be an independent committee
9
10 monitoring trial conduct, data or adverse events. Feedback from services will be provided to
11
12 investigators and adaptations made as necessary.
13
14
15

16 **Patient and public involvement in the research**

17
18 This trial was suggested by the Aboriginal Health Council SA, the peak organisation for South
19
20 Australian ACCHSs. Service participation in the trial must be approved by the Board of each local
21
22 ACCHS. The Board is recognised as representing patients and community in such decisions. As
23
24 described above, service staff will be consulted throughout their active support phase on how
25
26 project support can best be tailored. Results will be fed back bimonthly to services in an accessible
27
28 manner for all staff and board members, and services will have opportunity to provide comment on
29
30 draft outcome reports before publication.
31
32
33
34

35 **Dissemination of findings**

36
37 After feedback to participating ACCHSs, results will be disseminated via peer-reviewed
38
39 publications and conference presentations. Publications will be led by study investigators, research
40
41 students or staff supported by the investigators. The resources developed through this trial will also
42
43 be made freely available electronically at the end of the study period to support other health
44
45 services.
46
47
48
49

50 **Data sharing**

51
52 It is not possible to make the dataset publicly available because of ethical constraints. Alcohol is a
53
54 sensitive issue, and the data belongs jointly to the 22 services who take part. For the main
55
56 outcome report, statistical code used to analyse data will be made publicly available.
57
58
59
60

1
2 Authorship policy
3

4 All grant holders, and those involved in study conception and design, will co-author the main
5 outcome piece. Further articles based on sub-analyses or secondary research questions will be
6 authored by those directly involved in those questions. Acknowledgement will be given to
7 individuals involved in design of the main paper.
8
9
10
11
12
13

14 **Protocol amendments**
15

16 The trial's registration data are shown at Table 2 (ACTRN12618001892202). Any necessary
17 protocol amendments will be agreed on by study investigators, and where appropriate,
18 participating services. Then they will be registered with the Australian and New Zealand Clinical
19 Trials Registry.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. WHO trial registration data

Data category	Information
Primary registry and trial identification number	Australia New Zealand Clinical Trials Registry: ACTRN12618001892202
Date of registration in primary registry	2018-11-21
Secondary identifying numbers	APP1105339
Sources of monetary or material support	National Health and Medical Research Council (NHMRC; Australia)
Primary sponsor	The University of Sydney
Secondary sponsor	Royal Prince Alfred Hospital
Contact for public and scientific queries	Kate Conigrave, MBBS, FACHAM, FAFPHM, PhD kate.conigrave@sydney.edu.au
Public title	Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: a cluster randomised controlled trial
Scientific title	Increasing uptake of evidence-based management of unhealthy alcohol use in Aboriginal primary health care services: a cluster randomised controlled trial
Counties of recruitment	Australia
Health condition(s) or problem(s) studied	Hazardous alcohol use; Alcohol use disorders
Interventions	Health service support (including training, sharing learning between services); regular data feedback

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data category	Information
Key inclusion or exclusion criteria	Health services: <ol style="list-style-type: none"> 1. are Aboriginal Community Controlled Health services 2. deliver care to at least 1000 unique clients annually 3. use 'Communicare' as their practice software Data from clients 16 years and older are eligible for extraction
Study type	Interventional; Allocation: randomised; Primary purpose: prevention; Cluster randomised trial
Date of first enrolment	28/10/2016
Target sample size	22 services
Recruitment status	Complete
Primary outcomes	AUDIT-C screening rate
Key secondary outcomes	Brief intervention for alcohol rate

DISCUSSION

To our knowledge, this is the first large-scale randomised trial testing whether external support can enhance uptake of evidence-based alcohol care in services for Indigenous peoples. This study will add knowledge in the field of screening, early intervention and treatment for Indigenous peoples of Australia and inform future research and policy development. The findings are also likely to be relevant for Indigenous peoples internationally who have similar experiences of colonisation and inter-generational trauma. The research will also have relevance for non-Indigenous health services.

A strength of this study is its feasibility across a large number of services due to the use of routinely collected data. However, it is not within the project's resources to assess the quality of data recording. For example, it is likely that some brief discussions of alcohol use will go unrecorded, or will be entered as free text (which is not readily extractable), rather than in the specified fields ('clinical items'). Also, some forms of alcohol risk are not reflected in the AUDIT-C, for example, drinking while pregnant. While we examine health indicators as secondary outcomes (AUDIT-C score, BP, HbA1C, GGT), these may not be sensitive or specific enough to allow a confident assessment of any reduction in alcohol-related risk or improvement in client health. AUDIT-C scores may in fact become higher with improved quality of screening. In future, data linkage studies (e.g. examining hospital presentations) could allow more definitive assessment of health benefits of a model of service-wide support.

The model of support is designed to be culturally appropriate and collaborative, and tailored to individual service needs. The model is based on the use of champions within services, and feedback of routinely collected data, and so has potential to be sustainable, allowing for continuing quality improvement. The model also has potential to be scaled up for longer-term support of ACCHSs Australia-wide. The need for tailoring and flexibility in support elements provides challenges for analysis. However, this approach is ethically and practically necessary for work in partnership with Indigenous services. This type of local tailoring also has value for non-Indigenous clinical services in culturally and geographically diverse regions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

This work was supported by the NHMRC funding through a Project Grant (#1105339); a Centre of Research Excellence in Indigenous Health and Alcohol (#1117198); and a Practitioner Fellowship for K. Conigrave (#1117582). The funding body had no contribution to study design, writing of report, or in the decision to submit this report for publication; nor will they influence the submission of future reports. Thanks to Dr David Scrimgeour and to the Aboriginal Health Council of South Australia for suggesting this study. Also to Professor Sandra Eades, Professor Robert Sanson-Fisher and Mr Paul Ishiguchi for advice on study design and management.

Authors' contributions

KH refined the protocol for cultural appropriateness, drafted the protocol report; reviewed literature, recruited services, and will play a key role in training, qualitative data collection and qualitative analysis. KC, PH, NH, RI, KL conceived the study design. SW, NH assisted with ensuring design was culturally appropriate; KC,PH,RI, provide clinical expertise; BH and DJ provided guidance on Communicare™ use, data extraction and ACCHS support; BH assisted with service recruitment leads data extraction, and facilitates service liaison. TD developed the analysis plan, including power analyses, and provides ongoing advice. JC is responsible for merging and curating the data, and conducting t_1 quantitative analysis. KC, PH, RI, DG, TD, KL, SW, DJ are grant holders. All grant holders are on the project steering committee; all authors contributed to the development of the study protocol and approved this manuscript.

Declaration of interests

The principal investigators have no financial or other competing interests.

Trial Sponsor

The University of Sydney, NSW 2006, Australia and Sydney Local Health District

1
2 **Word Count:** 4605 (excluding tables, and acknowledgements onwards)
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. GBD 2016 Risk Factors Collaborators, *Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016*. Global Health Metrics, 2016. **Vol 390 September 16, 2017**.
2. Kirmayer, L.J., G.M. Brass, and C.L. Tait, *The mental health of Aboriginal peoples: transformations of identity and community*. Canadian Journal of Psychiatry, 2000. **45(7)**: p. 607-16.
3. Australian Bureau of Statistics/Australian Institute of Health and Welfare, *The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples*. 1999, ABS: Canberra.
4. Australian Institute of Health and Welfare, *Substance use among Aboriginal and Torres Strait Islander people*. 2011, Canberra: Australian Institute of Health and Welfare.
5. Australian Institute of Health and Welfare, *Aboriginal and Torres Strait Islander health performance framework, 2008 report: detailed analyses*. Cat. no. IHW 22. 2008, Canberra: AIHW.
6. Eckermann, A.-K., T. Dowd, and E. Chong, *Binan Goonj: bridging cultures in Aboriginal health*. 2010: Elsevier Australia.
7. World Health Organisation, *ICD-11 for mortality and morbidity statistics (ICD-11 MMS)* June 18 2018 ed. 2018, Geneva: World Health Organisation.
8. Glass, J.E., et al., *Rethinking alcohol interventions in health care: a thematic meeting of the International Network on Brief Interventions for Alcohol & Other Drugs (INEBRIA)*. 2017, BioMed Central.
9. Kaner, E.F., et al., *Effectiveness of brief alcohol interventions in primary care populations*. Cochrane database of systematic reviews, 2018(2).
10. Haber, P., et al., *Guidelines for the treatment of alcohol problems*. 2009, Canberra: Australian Government Department of Health and Ageing.
11. Chapman, C., et al., *Delay to first treatment contact for alcohol use disorder*. Drug and alcohol dependence, 2015. **147**: p. 116-121.
12. Solberg, L.I., M.V. Maciosek, and N.M. Edwards, *Primary care intervention to reduce alcohol misuse: ranking its health impact and cost effectiveness*. American Journal of Preventive Medicine, 2008. **34(2)**: p. 143-152.
13. Clifford, A., A. Shakeshaft, and C. Deans, *How and when health-care practitioners in Aboriginal Community Controlled Health Services deliver alcohol screening and brief intervention, and why they don't: A qualitative study*. Drug and Alcohol Review, 2012. **31(1)**: p. 13-19.
14. National Health and Medical Research Council, *Australian guidelines to reduce health risks from drinking alcohol*. 2009, Canberra, Australia: Commonwealth of Australia.
15. Reid, A.L.A., et al., *General practitioners' detection of patients with high alcohol intake*. British Medical Journal, 1986. **293**: p. 735-737.
16. d'Abbs, P., et al., *The Grog Mob: lessons from an evaluation of a multi-disciplinary alcohol intervention for Aboriginal clients*. Australian and New Zealand Journal of Public Health, 2013. **37(5)**: p. 450-456.
17. Morley, K.C., et al., *National trends in alcohol pharmacotherapy: findings from an Australian claims database*. Drug and alcohol dependence, 2016. **166**: p. 254-257.
18. Ornstein, S.M., et al., *Integration and sustainability of alcohol screening, brief intervention, and pharmacotherapy in primary care settings*. Journal of Studies on Alcohol & Drugs, 2013. **74(4)**: p. 598-604.
19. Harris, A.H.S., et al., *Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration*. Journal of Substance Abuse Treatment, 2017. **82**: p. 107-112.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
20. Campbell, M., J. Hunt, and AHMRC, *Aboriginal communities improving Aboriginal health: An evidence review on the contribution of Aboriginal Community controlled Health Services to improving Aboriginal health*. 2015, Sydney: Aboriginal Health and Medical Research Council, NSW.
21. Clifford, A., A. Shakeshaft, and C. Deans, *Training and tailored outreach support to improve alcohol screening and brief intervention in Aboriginal Community Controlled Health Services*. *Drug and Alcohol Review*, 2013. **32**(1): p. 72-79.
22. Australian Institute of Health and Welfare, *National Key Performance Indicators for Aboriginal and Torres Strait Islander primary health care: results from June 2016*, in *National key performance indicators for Aboriginal and Torres Strait Islander primary health care series no. 4*. 2017: Canberra.
23. Australian Institute of Health and Welfare, *AIHW National Key Performance Indicators Database User guide reporting period ending 30 June 2017*. 2017.
24. Bradley, K., et al., *AUDIT-C as a brief screen for alcohol misuse in primary care*. *Alcoholism: Clinical and Experimental Research*, 2007. **31**: p. 1208-17.
25. Babor, T.F., et al., *AUDIT. The Alcohol Use Disorders Identification Test - guidelines for use in primary care*. Second ed. WHO/MSD/MSB/01.6a. 2001, Geneva, Switzerland: World Health Organization, Department of Mental Health and Substance Dependence. 38.
26. Islam, M.M., et al., *Standardised alcohol screening in primary health care services targeting Aboriginal and Torres Strait Islander peoples in Australia*. *Addiction Science & Clinical Practice*, 2018. **13**:5.
27. Gray, D., et al., *Barriers and enablers to the provision of alcohol treatment among Aboriginal Australians: A thematic review of five research projects*. *Drug and Alcohol Review*, 2014.
28. Calabria, B., et al., *Identifying Aboriginal-specific AUDIT-C and AUDIT-3 cutoff scores for at-risk, high-risk, and likely dependent drinkers using measures of agreement with the 10-item Alcohol Use Disorders Identification Test*. *Addiction Science & Clinical Practice*, 2014. **9**(1): p. 17.
29. Keurhorst, M., et al., *Implementation strategies to enhance management of heavy alcohol consumption in primary health care: a meta - analysis*. *Addiction*, 2015. **110**(12): p. 1877-1900.
30. Si, D., et al., *Delivery of preventive health services to Indigenous adults: response to a systems-oriented primary care quality improvement intervention*. *Medical Journal of Australia*, 2007. **187**(8): p. 453-7.
31. Department of Health and Ageing, *Alcohol Treatment Guidelines for Indigenous Australians*. 2007, Commonwealth of Australia: Canberra.
32. National Health and Medical Research Council, *The NHMRC Road Map II: A strategic framework for improving the health of Aboriginal and Torres Strait Islander people through research*. 2010.
33. Conigrave, K.M., et al., *Traditional markers of excessive alcohol use [invited review]*. *Addiction*, 2003. **98**(Suppl. 2): p. 31-43.
34. Vancampfort, D., et al., *The prevalence of metabolic syndrome in alcohol use disorders: a systematic review and meta-analysis*. *Alcohol and alcoholism*, 2016. **51**(5): p. 515-521.
35. Australian Bureau of Statistics, *1216.0 - Australian Standard Geographical Classification (ASGC) - 2006* 2006.
36. Hintze, J., *PASS 12*. 2013, NCSS, LLC: Kaysville, Utah, USA.
37. Australian Bureau of Statistics, *Census of population and housing: characteristics of Aboriginal and Torres Strait Islander Australians, 2011*. 2076.0 2012, Canberra: ABS.
38. Panaretto, K., et al., *Evaluating performance of and organisational capacity to deliver brief interventions in Aboriginal and Torres Strait Islander medical services*. *Australian and New Zealand journal of public health*, 2010. **34**(1): p. 38-44.

- 1
2 39. Chikritzhs, T. and M. Brady, *Fact or fiction? ?A critique of the National Aboriginal and*
3 *Torres Strait Islander Social Survey 2002*. Drug and Alcohol Review, 2006. **25**(3): p. 277-
4 287.
- 5 40. Britt, H., et al., *General practice in Australia, health priorities and policy 1998 to 2008*.
6 General practice series no. 24; Cat. no. GEP 24. 2009, Canberra: AIHW.
- 7 41. Sanatinia, R., et al., *Brief intervention for alcohol misuse in people attending sexual health*
8 *clinics: study protocol for a randomized controlled trial*. Trials, 2012. **13**(1): p. 1-8.
- 9 42. Coulton, S., et al., *Screening and brief interventions for hazardous alcohol use in accident*
10 *and emergency departments: a randomised controlled trial protocol*. BMC health services
11 research, 2009. **9**(1): p. 114.
- 12 43. Paul, C., et al., *Achieving Type 2 diabetes action and collaborative change in Aboriginal*
13 *community controlled health services: outcomes of the ADACC cluster randomised trial*
14 *[abstract]*. International Journal of Behavioral Medicine, 2016. **23**: p. S142.
- 15 44. Carey M, B.H., Sanson-Fisher R, *The cycle of change: implementing best-evidence clinical*
16 *practice*. International Journal for Quality in Health Care, 2009. **21**(1): p. 37-43.
- 17 45. Kowalyszyn, M. and A. Kelly, *Family functioning, alcohol expectancies and alcohol-*
18 *related problems in a remote Aboriginal Australian community: a preliminary psychometric*
19 *validation study*. Drug and Alcohol Review, 2003. **22**(1): p. 53-59.
- 20 46. Lee, K., et al., *Handbook for Aboriginal Alcohol and Drug Work*. 2012, Sydney, NSW:
21 University of Sydney.
- 22 47. Haber, P., et al., *Quick reference guide to the treatment of alcohol problems: companion*
23 *document to the guidelines for the treatment of alcohol problems*. 2009, Prepared for the
24 Australian Government Commonwealth Department of Health and Ageing: Canberra. p. 9.
- 25 48. Hirsch, A., et al., *Every door closed: Barriers facing parents with criminal records*. 2002,
26 Washington: Community Legal Services, Inc.
- 27 49. Ministerial Council on Drug Strategy, *National Drug Strategy Aboriginal and Torres Strait*
28 *Islander Peoples Complementary Action Plan 2003-2009 (Background Paper)*. 2006,
29 Commonwealth of Australia: Canberra.
- 30 50. Sibthorpe BM, et al., *The demise of a planned randomised controlled trial in an urban*
31 *Aboriginal medical service*. Medical Journal of Australia, 2002. **176**(6): p. 248-9.
- 32 51. NSW Health Department, *A Framework for Building Capacity to Improve Health*. 2001.
- 33 52. Melanie Birks, Y.C., Karen Francis, *Memoing in qualitative research. Probing data and*
34 *processes*. Journal of Research in Nursing, 2008. **13**(1): p. 68–75.
- 35 53. Morse, J.M. and P.A. Field, *Qualitative research methods for health professionals*. 1995.
36 **2nd edition**: p. 254
- 37 54. Glaser, B. and A. Strauss, *The discovery of grounded theory: strategies for qualitative*
38 *research*. Chicago: Aldine Publishing Company, 1967.
- 39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **Figure Legends**
3
4

5 Figure 1. Project principles – embedding mainstream evidence into a cultural care approach
6


7 Figure 2. Flow diagram for the trial
8

9 Figure 3. Three of the elements used to feedback alcohol screening data to ACCHSs
10


11 Figure 4: Project Timeline: SPIRIT schedule of enrolment, interventions, and assessments for the
12
13
14 trial
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




review only



1. Are you meeting your AUDIT-C screening goal?




2. How many clients your service is screening



Screening rate over 12 months (out of clients aged 16+ who have attended in the past year)

3. How is your AUDIT-C screening rate going over time?



Screening rate for each 2-month period

Study period							
	Enrolment	Allocation	Post-allocation				
TIMEPOINT	<i>t</i> -1 (Feb 16) Oct 2016 to Jun 2017	16/06/17	<i>t</i> ₀ 29/8/17 Year 1	<i>t</i> ₁ 28/8/18 Year 2	<i>t</i> ₂ 14/8/19 Year 3	<i>t</i> ₃ 13/8/20 Year 4	Close out 28/4/21
ENROLMENT:							
Eligibility screen	X						
Informed consent	X						
Allocation		X					
INTERVENTIONS:							
Early support services							
Late support services (wait-list control)							
ASSESSMENTS:							
Baseline/outcome variables Retrospectively collected for 2-monthly periods [†] from Feb 2016 to Feb 2021: AUDIT-C screening rate; provision of brief interventions [‡] , counselling; prescriptions for acamprosate, naltrexone, disulfiram; AUDIT-C results; systolic BP; GGT; HbA1c [§]	X	X	X	X	X	X	X

*Data will be retrospectively extracted for the 12-month period before the start of the support (the intervention). All data used in this study are routinely collected clinical data, extracted from the practice software ('Communicare'). † Data will be extracted on the 28th day of every second month. The first census date (*t*₁) is one year after the start of the intervention; *t*₂₋₄ are other census points. ‡ Unhealthy alcohol use = hazardous consumption or alcohol use disorders § Blood test results (GGT, HbA1c) are only available when these have been routinely conducted ^αActive support phase ^βMaintenance support phase



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	i
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	iv; Table 2 (p13)
	2b	All items from the World Health Organization Trial Registration Data Set	Table 2 (p13)
Protocol version	3	Date and version identifier	iv
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	i, 15
	5b	Name and contact information for the trial sponsor	15
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	i, 15

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 1 - 3
4 rationale studies (published and unpublished) examining benefits and harms for each intervention
5

6 6b Explanation for choice of comparators 2
7

8 Objectives 7 Specific objectives or hypotheses 3
9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 3
12
13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 3
17 be collected. Reference to where list of study sites can be obtained
18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 4
20 individuals who will perform the interventions (eg, surgeons, psychotherapists)
21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 6 – 9; Figure 2 (p3)
23 administered
24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 12
26 change in response to harms, participant request, or improving/worsening disease)
27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 10
29 (eg, drug tablet return, laboratory tests)
30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial N/A
32
33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 4
36 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
37 efficacy and harm outcomes is strongly recommended
38
39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 6, Figures 2 (p3)
41 participants. A schematic diagram is highly recommended (see Figure)
42
43

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	5
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	4
5				
6	Methods: Assignment of interventions (for controlled trials)			
7				
8	Allocation:			
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	5
11				
12				
13				
14				
15	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	5
16				
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	4-5
21				
22				
23	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	6
24				
25				
26		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
27				
28				
29				
30	Methods: Data collection, management, and analysis			
31				
32	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9-10
33				
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	10
39				
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	10
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11-12
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11-12
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation).	12
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed **It's mainly used where treatment can cause harms, here minimal risk**	12
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	10
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	12
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4-5
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	5
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial. (**do we need to mention data destroyed 7 years after last publication)?	10
8				
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
12				
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	13
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	13
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	13
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendices 1-4
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA
36				
37				

38
39 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
40 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
41 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.
42